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Abstract 
RIDA FATIMA SAEED 
Investigation of inhibitors of polysialyltransferase as novel therapeutics 
for neuroblastoma  
Keywords: Polysialic acid, Neural Cell Adhesion Molecule, Neuroblastoma, 
Polysialyltransferase, Metastasis, Invasion, Cancer therapeutics, Transwell 
invasion assay, Sialic acid expression 
Polysialic acid is a unique carbohydrate that decorates the surface of the neural 
cell adhesion molecule. Polysialic acid is an onco-developmental antigen, 
expressed in tumours principally of neuroendocrine origin, notably 
neuroblastoma, strongly correlating with invasion and metastasis. 
Polysialylation is regulated by two polysialyltransferase enzymes, PST 
(ST8SiaIV) and STX (ST8SiaII), with STX dominant in cancer. Post-
development polysialic acid expression is only found at low levels in the brain, 
thus this could be a novel target for cancer therapy. It is hypothesized that 
inhibition of polysialyltransferase could lead to control of tumour dissemination 
and metastasis. The aims of this thesis were to develop tools and in vitro 
assays to screen novel polysialyltransferase inhibitors. A panel of tumour cell 
lines were characterised in terms of growth parameters (using the MTT assay) 
and polysialic acid expression. This includes a pair of isogenic C6 rat glioma 
cells (C6-STX and C6-WT) and naturally polysialic acid expressing 
neuroblastoma cells (SH-SY5Y). Following this, an in vitro assay was validated 
to screen modulation of polysialic acid expression by removing pre-existing 
polysialic acid expression using endoneuraminidase N and evaluated the 
amount of re-expression of polysialic acid using immunocytochemistry. Then, a 
functional assay was developed and validated for invasion, the matrigel 
invasion assay. Cytidine monophosphate (tool compound) significantly reduced 
polysialic acid surface expression and invasion. A panel of six novel 
polysialyltransferase inhibitors was screened for cytotoxicity, polysialic acid 
surface expression and invasion. Of the potential polysialyltransferase inhibitors 
evaluated, ICT3176 and ICT3172 were identified from virtual screening of 
Maybridge library and were emerged as the most promising inhibitors, 
demonstrating significant (p<0.05) reduction in cell-surface polysialic acid re-
expression and invasion in polysialic acid expressing cells. Furthermore, the 
specificity of compounds for polysialyltransferase (α-2,8-sialyltransferase) over 
other members of the wider sialyltransferase family (α-2,3- and α-2,6-
sialyltransferases) was confirmed using differential lectin staining. These results 
demonstrated that small molecule inhibitors as STX is possible and provides 
suitable in vitro cell based assays to discovery more potent derivatives. 
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CHAPTER ONE 
 
 
1  Introduction 
1.1 Aetiology of Cancer 
Cancer is a multi-faceted disease characterised by uncontrollable cell 
proliferation (Hanahan and Weinberg, 2011). There have been more than 200 
different types of cancer identified, caused by random mutations of genes or 
exposure to environmental changes (Hanahan and Weinberg, 2000). 161,823 
deaths in the UK were due to cancer in 2012, of which half were from lung, 
bowel, breast and prostate cancers (CRUK, 2014).  
Cancer is rare among children, affecting between 70 and 160 per million 
children 0-14 years (Stiller, 2004). There are histological differences between 
adult and childhood cancer, and therefore cancers been classified according to 
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histology rather than a primary site (Stiller, 2004). The „International 
Classification of Childhood Cancer‟ includes 12 major groups sub-divided into 
47 sub-groups. These are based on morphology and topography as stipulated 
in the third edition of the International Classification of Diseases for Oncology 
(ICD-O) (Steliarova-Foucher et al., 2005).  
These cancers have different origins but their characteristic biological ability to 
promote tumour growth and their metastatic dissemination provides the 
fundamental foundation, which helps to understand the complex biology of 
cancers.  
The major groups of childhood cancers include leukaemia, lymphomas, brain 
and spinal tumours. It also includes sympathetic nervous system tumours, 
retinoblastoma, kidney tumours, hepatic tumours, malignant bone tumours, soft 
tissue sarcomas, gonadal and germ-cell tumours, epithelial tumours, as well as 
other and unspecified malignant cancers (Stiller, 2004). The most common 
extra-cranial cancer in children which is also the second-most common 
paediatric cancer is neuroblastoma (Park et al., 2010). 
1.2 Neuroblastoma 
Neuroblastoma is a paediatric cancer affecting the sympathetic nervous system 
(Maris et al., 2007). Neuroblastoma is the most deadly solid tumour in children 
causing 7 to 10% of paediatric oncology deaths. Many cases of neuroblastoma 
occur in children either during infancy or early childhood (Brodeur, 2003). The 
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incidence of neuroblastoma is relatively slightly higher in boys than in girls 
(Heck et al., 2009). 
1.2.1 Clinical presentation 
Most neuroblastoma is characterised by the presence of undifferentiated tumour 
cells called neuroblasts (Brodeur, 2003). Neuroblastoma arises from neural 
crest cells, which are progenitor cells of the sympathetic nerves. These migrate 
from the neural crest and from sympathetic ganglia, the chromaffin cells of the 
adrenal medulla and the paraganglia (Park et al., 2010).  
The symptoms and clinical presentation of neuroblastoma patients are a 
common indication of tumour location (Ishola and Chung, 2007). The clinical 
presentation reflects the primary tumour location and the intensity of the 
disease (Weinstein et al., 2003). 65% of primary tumours are found in the 
abdomen (adrenal glands) and other common sites are the neck, chest and 
pelvis (Maris et al., 2007).  
The clinical staging classification includes localised tumours and those which 
have metastasised are described in section 1.2.2. Localised tumours occur in 
40% of patients and range in diagnosis of an intra-adrenal mass to large 
invasive tumours along with the sympathetic chains (Maris et al., 2007). The 
intra-abdominal mass may be an incidental finding on ultrasonography. There 
are approximately 5% patients who suffer from the signs of neurological 
impairment which includes motor weakness, pain or sensory loss.  
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Neuroblastoma is a metastatic disease which burdens the system extensively. 
Patients with localised disease show no symptoms but patients with metastatic 
disease have symptoms, namely fever and bone pain often caused by tumour 
dissemination (Weinstein et al., 2003).  
1.2.2 Classification 
Clinically, there are three patterns of neuroblastoma which include rapid 
progression of the tumour into a life-threatening illness, maturation to benign 
ganglioneuroma and spontaneous regression (Heck et al., 2009). The 
progression and typology of neuroblastoma, like many other cancers, is defined 
by stages. In 1984, Shimada and colleagues described the staging classification 
relating to tumour (histological features or biopsy) which has shown high levels 
of urinary catecholamines as listed in Table 1.1 (Shimada et al., 1984). 
Stage 1 is localised tumours that can be completely resected whereas stage 2 
and stage 3 involve tumours which can be partially resected with or without 
regional nodules. These stages are dependent on the potential for removing the 
volume of tumour resectable, the local invasion and lymph nodes.  
Stage 4 can be defined as dissemination of tumours to distant lymph nodes or 
bone marrow. The striking phenotypes of neuroblastoma in stage 4S (S for 
special) was first described in 1971 (D'Angio et al., 1971). In infants (stage 4S) 
is defined as the dissemination patterns limited to liver, skin and minimal bone 
marrow. Spontaneous regression is the most enigmatic clinical feature of 
neuroblastoma and is associated with stage 4S. Spontaneous regression of 4S 
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tumours is reported with myelocytomatosis viral related oncogene, 
neuroblastoma derived (MYCN) amplification (Tonini et al., 1997) or lack of 
MYCN amplification Stage 4S tumour (Nickerson et al., 2000). 
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International Neuroblastoma Staging System 
Stage 1 
 
Localised tumour with complete gross excision; with/out microscopic 
residual disease; identifiable ipsilateral and contralateral lymph 
nodes is negative microscopically 
 
Stage 2A 
 
Localised tumour with incomplete gross excision; representative 
ipsilateral non-adherent regional lymph nodes negative for tumour 
microscopically 
 
Stage 2B 
 
Localised tumour with/out complete gross excision; with ipsilateral 
non-adherent lymph nodes; positive for tumour; enlarged 
contralateral lymph nodes must be negative microscopically 
 
Stage 3 
 
Unresectable unilateral tumour infiltrating across the midline; with/out 
regional lymph nodes involvement; localised unilateral tumour with 
contralateral regional lymph nodes; midline tumour with bilateral 
extension by unresectable (infiltration) or by lymph nodes 
involvement 
 
Stage 4 Primary tumour (any) dissemination to distant lymph nodes, bone 
marrow, skin or other organs 
 
Stage 4S 
 
Localised primary tumour (defined for stage 1, 2A, 2B) with 
dissemination limited to skin, liver or bone marrow (limited to 
infants<1 year of age)  
 
Table 1.1: Schematic illustration of the International Neuroblastoma 
Staging System (INSS). Taken from (Subhasree Roy Choudhury, 2012). 
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1.2.3 Prognostic factors 
The International Neuroblastoma Surgical Staging (INSS) refers to the 
surgically based staging systems and has limitations including: staging patients 
are found more in high-neuroblastoma treatment and overlapping types of 
treatment. Due to these limitations, the International Neuroblastoma Risk Group 
(INRG) was developed in 2005, based on the clinical and biological features of 
11,054 neuroblastoma patients across the world. The list includes age at 
diagnosis, INSS stage, tumour histopathology, DNA index (ploidy) and MYCN 
amplification, which are considered to be significant risk factors for 
neuroblastoma (Cohn et al., 2009, Park et al., 2010). These clinical and 
biological prognosis factors are statistically significant and clinically relevant for 
prognostic evaluation (Table 1.2) (Cohn et al., 2009).  
Neuroblastoma prognosis is dependent on age and location of the tumour, but 
the most important prognostic factor is the stage of the disease (Weinstein et 
al., 2003). Age is also an important prognostic factor and there is a worse 
prognosis for patients older than 1 or 2 years, especially when diagnosing 
disseminated disease (Park et al., 2010). Heck et al (2009) identified 47 articles 
from the search engine PubMed and summarised the risk factors in pregnancy 
for the later development of neuroblastoma in children. These included use of 
alcohol and effects of intake of vitamin during pregnancy or intake leading to 
allergic reactions prior to the diagnosis of neuroblastoma (Heck et al., 2009). 
These studies provide a complicated understanding of the causation of 
neuroblastoma and further studies are still required.  
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Table 1.2: Children Neuroblastoma Risk Group (INRG) based on clinical 
features. Taken from (Park et al., 2010). 
Stage Risk group Age (months) Ploidy MYCN Shimada 
1 Low risk 
 
    
2A/2B Low risk 
 
  NA  
2A/2B High risk 
 
  A  
3 Intermediate risk 
 
<18  NA  
3 Intermediate risk 
 
≥18  NA FH 
3 High risk   A 
 
 
3 High risk 
 
≥8  NA UH 
4 High risk <12  A 
 
 
4 Intermediate risk 
 
<12  NA  
4 High risk 
 
12 to < 18 
 
 A 
 
 
4 High risk 
 
12 to < 18 
 
DI = 1 
 
  
4 High risk 
 
12 to < 18 
 
  UH 
 
4 Intermediate risk 
 
12 to < 18 
 
DI > 1 
 
NA FH 
 
4 High risk 
 
≥18 
 
   
4S Low risk 
 
<12 
 
DI > 1 
 
NA 
 
FH 
4S Intermediate risk 
 
<12 
 
DI = 1 
 
NA 
 
 
4S Intermediate risk 
 
<12 
 
 NA 
 
UH 
4S High risk 
 
<12 
 
 A  
 
Keywords: Blank: Any field; DI: DNA Index; FH: Favourable Histology; 
UH: Unfavourable Histology; A: Amplified; NA: Not Amplified; Shimada 
histopathologic classification 
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1.2.4 Diagnostic tests  
Different types of visual and physical symptoms and screening tests are used 
for the diagnosis of neuroblastoma. This includes biopsy, testing for urine or 
serum metabolites (catecholamine), metastatic spread, and size of tumour 
monitored by computed tomography and magnetic resonance imaging (Maris et 
al., 2007, Park et al., 2010). 
Chest radiographs allow tumour detection whereas ultrasonography allows 
determination of the nature of the tumour (Ishola and Chung, 2007). Computed 
tomography (CT) can also be used for the clinical assessment of the disease in 
the abdomen, pelvis or mediastinum regions (Maris et al., 2007). Nearly 80% of 
neuroblastoma patients produce urinary catecholamines. The metabolites of 
catecholamine; homovanillic acid (HVA) and vanillylmandelic acid (VMDA) are 
assessed for the diagnostic screening of the disease (LaBrosse et al., 1980, 
Laug et al., 1978).  
Neuroblastoma is often a radiation sensitive disease and there has been 
considerable interest in using radioactive isotope-labelled, which are taken by 
tumours, particularly meta-iodobenzylguanidine (MIBG). This is a 
norepinephrine analogue taken up by high catecholamine excreting organs. 
Therefore, radiolabelled 131-I MIBG allows imaging of neuroblastoma and could 
have a potential for therapy in high-risk neuroblastoma patients (Riad et al., 
2009). 
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1.2.5 Treatments 
Presently, various therapeutic options are available for neuroblastoma, which 
depend on the patient‟s age and stage of the disease. Treatment of patients 
with stage 4 disease remains the biggest challenge for paediatric oncologists. 
Currently, the treatment options consist of chemotherapy, radiotherapy or local 
control with surgery. 
1.2.5.1 Surgery 
The general surgical approach is used for resection, staging of tumour and 
biopsy. Different surgical procedures are required for different stages of 
neuroblastoma, which are described in Table 1.2. In the early stages of 
neuroblastoma (stages 1, 2A, 2B) surgery resection is preferred option. This 
may be used in 4S stages since tumour may be differentiate and spontaneously 
regress without any specific treatment (Ishola and Chung, 2007). 
1.2.5.2 Chemotherapy 
Chemotherapy is mainly used by the patients who have relapsed after surgery 
in INSS stage 1. The typical chemotherapeutic agents used are 
cyclophosphamide, iphosphamide, vincristine, doxorubicin (adriamycin), 
cisplatin, carboplatin, etoposide (VP-16) and melphalan that are used in 
different combinations (Ishola and Chung, 2007). For example, myeloablative 
chemotherapy has been used as a combined therapy with 131-I MIGB for 
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treating INSS 3 and INSS 4 stage patients with refractory neuroblastoma 
(Matthay et al., 2006). 
In the advanced stage tumours, combined chemotherapy reduced the tumour 
size, which can be resectable, but often failed to eradicate the tumour. Some 
cases of high-risk neuroblastoma patients (INSS 3 and INSS 4), where 
neuroblastoma is refractory to chemotherapy are aggressively treated by bone 
marrow-ablative therapy with melphalan or total body radiation followed by bone 
marrow transplant, which have shown some success (Matthay et al., 2006). 
However, these therapies have unfavourable side-effects.  
1.2.5.3 Radiotherapy 
Neuroblastoma is considered to be radiosensitive tumour and radiotherapy has 
shown to be applied with minimal residual disease (MRD) therapy and surgery 
(Modak and Cheung, 2010). Radiotherapy and chemotherapy are often used 
together for improving the resectability of advanced stage neuroblastoma 
(Ishola and Chung, 2007). 
1.2.5.4 Myeloablative therapy 
Several clinical trials have shown that myeloablative therapy combined with 
bone marrow transplant improve high-risk patients‟ neuroblastoma outcomes. 
With this therapy, the relapse rate can be reduced in neuroblastoma and further 
intensification of myeloablative therapy may result in better outcomes (Park et 
al., 2010). 
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1.2.5.5 Other new therapies 
Recently, new therapies have also been developed and are having a huge 
impact on the clinical treatments of neuroblastoma. The most common 
biotherapy adjuvant is the 13-cis-retinoic acid (isotretinoin, 13-cis-RA), a 
synthetic retinoid that is used in treating high-risk neuroblastoma (Park et al., 
2010). 
New therapeutic agents for neuroblastoma, including topotecan (topoisomerase 
I inhibitor) or combinational therapy with carboplatin have a potential use 
against neuroblastoma for relapse patients (Weinstein et al., 2003). Other new 
approaches include using immunotherapy (targeting disialoganglioside GD2) or 
angiogenesis inhibitors (Maris et al., 2007).  
Despite the availability of various treatments and diagnostic tools, 
neuroblastoma still continues to have a poor prognosis rate. The majority of 
neuroblastoma patients are younger than a year old, and the majority die as the 
disease progresses. Less than 40% of children survive up to 5 years 
(Subhasree Roy Choudhury, 2012). This emphasizes the urgent need for 
developing new therapeutic strategies to treat neuroblastoma.  
Hanahan and Weinberg (2000) proposed the „Hallmarks of the Cancer‟ which 
consist of characteristics relating to a biological ability to promote tumour growth 
and tumour dissemination, providing us the fundamental basis to our 
understanding of cancer. This research is primarily focused on inhibiting 
invasion and metastasis. 
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The dissemination of tumour cells from primary lesion sites is the main cause of 
cancer mortality and morbidity. Targeting this hallmark could provide a novel 
therapeutic opportunity. Good anti-metastatic drugs could be developed through 
understanding the biology of the tumour and different molecules playing a role 
in tumour progression.  
One novel target is aberrant glycosylation in neoplastic tissues, especially 
abnormal sialylation expression, which is a particular feature of the malignant 
tumour, affecting the adhesive interactions of cancer cells and provides 
favourable conditions for tumour dissemination (Rambaruth and Dwek, 2011). 
1.3 Tumour glycocalyx 
Tumour progression and metastasis is a multi-step process. An important 
process in the metastatic cascade is the role of cell adhesion molecules 
involved in protein-glycan interactions reviewed in Rambaruth and Dwek (2011). 
Glycans play a role in cell-adhesion, cell-cell and cell-matrix communication, 
and in detachment from the extracellular matrix and cell mobility for invasion 
(Peracaula et al., 2008). Some aberrant glycans have been reported in tumour 
cells assisting in tumour development and progression (Fuster and Esko, 2005). 
Various carbohydrates decorate the surface of mammalian cells (Figure 1.1), 
collectively known as the glycocalyx and individually as „glycans‟ which involve 
the formation of the oligo- and polysaccharides from monosaccharides (Yarema 
and Bertozzi, 2001). Glycans can be classified either as N-linked forming a 
glycosidic bond with asparagine or O-linked which form a glycosidic bond with 
CHAPTER ONE 
 
    
 
14 
 
serine or threonine. They can be branched and regularly terminate with a single 
sugar unit belonging to the sialic acid family, playing a diverse functional role in 
cell-cell interaction (Fuster and Esko, 2005). 
The aberrant expression of glycocalyx components has been linked to tumour 
progression. One key component of the glycocalyx is polysialic acid (polySia), 
which was first described by Finne in 1982 as a major component of developing 
vertebrate brains. PolySia is a carbohydrate polymer of sialic acid 
predominantly attached to the neural cell adhesion molecule (NCAM) (Fukuda, 
1996, Kiss and Rougon, 1997). 
Many studies have indicated the expression of modified NCAM by polySia in 
cancers including neuroblastoma, rhabdomyosarcoma, Wilm‟s tumour, small-
cell lung and non-small cell lung cancer (Fukuda, 1996, Glüer et al., 1998a), 
where it correlates with tumour progression and metastasis (Cheung et al., 
2006, Daniel et al., 2001, Gluer et al., 1998c, Tanaka et al., 2000). Since, there 
is a positive correlation between polysialylated NCAM and cancer metastasis, 
developing an anti-metastatic drug against aberrant polySia-NCAM could hold a 
promising future. 
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Glycoproteins either branched with (a) N-linked glycans (conjugated bond to 
asparagine) or with (b) O-linked glycans (covalently linked to serine or 
threonine). (c) Glycosphingolipids, which consist of glycans linked to ceramide. 
Glycosaminoglycans can either occur as free chain (hyaluronan: (e) or 
covalently linked with proteoglycan core protein (heparan sulphate: (f). 
Coloured geometric symbols are used to represent various sugars. Taken from 
(Fuster and Esko, 2005).  
Keywords: Glc: Glucose; Gal: Galactose; Man: Mannose; GlcNAc: N-
acetylglucosamine; GalNAc: N-acetylgalactosamine; GlcA: Glucuronic acid; 
Fuc: Fucose; Xyl: Xylose; Sia: Sialic acid. 
Figure 1.1: Unique glycans involved in tumour progression. 
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1.4 Neural cell adhesion molecule 
Nearly 40 years ago, the neural cell adhesion molecule (abbreviated as NCAM; 
CD56) was identified as a cell surface glycoprotein (Rutishauser et al., 1976). In 
subsequent years, NCAM was isolated, purified and fully characterised where it 
was shown to be acting as an adhesion mediator in retina cells (Hoffman et al., 
1982, Thiery et al., 1977). NCAM belongs to the immunoglobulin superfamily, 
which is predominantly present in the central and peripheral nervous system 
(Angata and Fukuda, 2003, Jensen and Berthold, 2007).  
NCAM is encoded by a single gene and is found on chromosome 11 in humans 
and on chromosome 9 in mice (Nguyen et al., 1986). Alternative RNA splicing of 
NCAM results in three major isoforms, namely NCAM-180, NCAM-140 and 
NCAM-120 (Figure 1.2) (Gascon et al., 2007). These isoforms have different C-
terminal regions: the NCAM-120 isoform, connected by a 
glycosylphosphatidylinositol (GPI) anchor to the cell membrane, is 
predominantly expressed in normal and well differentiated tissues. The NCAM-
140 and NCAM-180 isoforms have transmembrane domains and are found 
predominantly in less differentiated or malignant cell types (Jensen and 
Berthold, 2007). NCAM isoforms have identical N-terminal extracellular regions 
consisting of five immunoglobulin-like (Ig1-5) domains and two fibronectin type 
III domains (Jensen and Berthold, 2007, Bonfanti, 2006). Furthermore, these 
isoforms are expressed in different cell types, for instance, NCAM-120 is 
expressed in glial, and NCAM-140 in neuron and glial and NCAM-180 is found 
in neurons (Noble et al., 1985). 
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Figure 1.2: Schematic illustration of molecular characteristics of NCAM.  
The NCAM protein core is attached to polySia via two N-glycosylation sites, 
containing five immunoglobulin-like domains (Ig) and two fibronectin-type III 
repeats (FnIII). NCAM isoforms NCAM-180 and NCAM-140 are 
transmembrane protein whereas NCAM-120 linked by GPI anchor result by an 
alternative splicing. (Kleene and Schachner, 2004). 
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1.5 Sialic acid 
The wider sialic acid family encompasses approximately fifty naturally occurring 
sugars, the most common of which is N-acetylneuraminic acid („sialic acid‟: Sia) 
found in humans (Kohla and Schauer, 2005). Sia is a negatively charged nine-
carbon sugar, commonly found on the cell-surface, at glycan termini. Depending 
on the chemical linkage, Sia forms O- or N-linked glycans, attached either to 
galactose (Gal) or N-acetylgalactosamine (GalNAc) via α-2,3-/α-2,6- linkages or 
α-2,8/α-2,9-linkages in the case of polysialic acid by specific enzymatic 
reactions (Ivan Martinez-Duncker, 2011). Therefore, any changes in glycan 
expression such as enzyme dysfunction activity can lead to rare congenital 
diseases or cancer (Galeano et al., 2007, Li et al., 2010).  
1.6 Polysialic acid 
Polysialic acid (polySia) is composed of a unique carbohydrate, which is a linear 
homopolymer of α-2,8-linked sialic acid expressed predominantly in the 
embryonic brain (Brusés and Rutishauser, 2001, Finne, 1982, Bonfanti, 2006). 
A post-translational process adds polySia on NCAM, forming simple and large 
molecules and has a range from 8 to 100 monomers (Mühlenhoff et al., 1998, 
Rutishauser and Landmesser, 1996). 
PolySia has three main building units: 5-N-acetylneuraminic acid (Sia), 5-N-
glycolylneuraminic acid (Neu5Gc) and 5-deamino-3, 5-deoxyneuraminic acid (2-
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keto-3-deoxynonulosonic acid, Kdn) (Mühlenhoff et al., 1998) shown in Figure 
1.3A.  
In mammals, the majority of polySia is expressed on NCAM (see Figure 1.3B). 
However, polySia expression has been detected on the voltage-sensitive 
sodium channel alpha-unit and secreted glycoprotein in mammalian milk CD36 
(Zuber et al., 1992, Yabe et al., 2003). In addition to this, polysialylated NCAM 
has been found in other cells including oligodendrocytes, astrocytes, 
neuroblasts, glial precursors and on the immune system including human 
leukocyte to modulate immune response (for details, see (Janas and Janas, 
2011, Drake et al., 2008)). 
1.6.1 Biological and structural features of polySia 
The carboxyl region of Sia has been used to determine the biological features of 
polySia, consisting of a negative charge, covering a large space and sustaining 
water and ionic molecules (Gascon et al., 2007, Kiss and Rougon, 1997, 
Rutishauser and Landmesser, 1996). PolySia attenuates NCAM interactions, 
modulating cell adhesion properties (Rutishauser and Landmesser, 1996, Kiss 
and Rougon, 1997).  
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(A) Polysialic acid three main building blocks, including 5-N-acetylneuraminic 
acid (Sia), 5-N-glycolylneuraminic acid (Neu5Gc) and 5-deamino-3,5-
dideoxyneuraminic acid (2-keto-3-deoxynonulosonic acid, Kdn). Taken from 
(Mühlenhoff et al., 1998). (B) Representation of the polysialylated neural cell 
adhesion molecule (NCAM). NCAM has six N-glycosylation sites (black arrows) 
and 5th and 6th N-glycans carry one or more polySia chains, a linear 
homopolymer of α-2,8-linked sialic acid. PolySia chains are linked with α-2,3 or 
α-2,6 first and have more than 90 monomers forming polyanions (grey spheres 
highlighted negatively charged carboxyl group). This increases the 
hydrodynamic volumes of NCAM and effect the carrier binding such as polySia 
binding to NCAM changes the adhesion to repelling molecule. From (Schnaar et 
al., 2014). 
(B) 
Figure 1.3: Schematic presentation of polysialylated NCAM. 
Kdn Neu5Gc Sia 
(A) 
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1.6.2 PolySia biosynthesis by polysialyltransferases 
The biosynthesis pathway for polySia begins in the cytosol, where UDP-N-
acetylglucosamine (UDP-GlcNAc) is converted to N-acetylmannosamine 
(ManNAc). In mammals, ManNAc is phosphorylated forming ManNAc-6-
phosphate (ManNAc-6P). The condensation reaction of ManNAc or ManNAc-6P 
with phosphoenolpyruvate (PEP) forms neuraminic acid or neuraminic acid-9P. 
Then, neuraminic acid-9P is dephosphorylated resulting in neuraminic acid 
(Sia). The final reaction occurs in the nucleus, involving the conjugates of Sia to 
cytidine monophosphate (CMP-Sia) and cytosine triphosphate (CTP).  
CMP-Sia enters the Golgi lumen using the CMP-Sia transporter (CMP-SiaTr), 
acting as a substrate donor to more than 20 human sialyltransferases (STs) that 
incorporate into the non-reducing end of glycans (Ivan Martinez-Duncker, 
2011).  
Polysialyltransferases (polySTs) use the activated Sia as a substrate to form 
polysialylated NCAM inside the Golgi apparatus (Bork et al., 2005) and added 
to glycans via α-2,8 linkages. PolyST belongs to the wider sialyltransferase 
family, which also has α-2,3-ST and α-2,6-ST. For that reason, polySTs are 
responsible for the synthesis of polySia by adding α-2,8-linked Sia to an α-2,3-
linked Sia followed by multiple α-2,8-linked Sia residues (Angata et al., 1998).  
PolySia is synthesised by two polysialyltransferase (polyST) enzymes, named 
PST (ST8Sia IV) and STX (ST8Sia II) respectively reviewed in (Tsuji, 1996, 
Angata and Fukuda, 2003, Mühlenhoff et al., 1998). PST and STX appear to 
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share enzymatic properties and have 59% sequence identity at the amino acid 
level. Each contains features typical of sialyltransferases including the stem 
domain, catalytic domain and transmembrane domains shown in Figure 1.4 
(Gascon et al., 2007). They also have polySTs motifs named 
polysialyltransferase domain (PSTD) and the polybasic region (PBR). The 
PSTD activity depends on 32 amino acids motifs, which is required to form 
polysialylation capacity shown in Figure 1.4B (Nakata et al., 2006).  
The expression of enzymes is tissue-specific and cell-specific, suggesting 
distinct roles during development (Angata and Fukuda, 2003, Ong et al., 1998). 
PolySia is added by both polyST enzymes on the Ig5 domain of NCAM, which 
contains six N-linked glycan sites (Figure 1.4A) (Angata et al., 1998).  
Angata et al (1998) attempted to determine the individual roles of the polyST 
enzymes and revealed that both enzymes synthesised polySia efficiently on 
NCAM. Their results showed the polyST enzymes specificity on N-glycan 
structures in NCAM.  
Interestingly, polySTs also have auto-polysialylation activity and it has been 
hypothesised that polySia chains are transferred en bloc to the acceptor 
(NCAM) but the auto-polysialylation role is still indistinct (Angata and Fukuda, 
2003). Mutagenesis studies carried out on auto-polysialylation showed a 
significant reduction of polySia-NCAM biosynthesis, suggesting the link 
between the synthesis of polySia on NCAM and auto-polysialylation 
(Mühlenhoff et al., 1998, Close et al., 2001). 
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Angata and Fukuda (2003) later proposed that PST and STX work 
cooperatively and their mutual presence results in higher and longer polySia 
polymer chains. Both PST and STX produce polySia but the degree of 
polysialylation for STX (~40 sialic acid residues) was lower than that observed 
with PST (~60 sialic acid residues) (Angata and Fukuda, 2003, Gascon et al., 
2007). 
STX has been proposed as a potential marker to detect metastatic 
neuroblastoma cells and is thought to be the major enzyme that synthesises 
polySia in tumours (Cheung et al., 2006).  
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(A) NCAM is the major polySia binding acceptor. In vitro, all isoforms are 
polysialylated on the Ig5 domain. (B) Schematic presentation of 
polysialyltransferases STX and PST. Both enzymes consist of a stem region, a 
transmembrane domain (TMD), an NH2-terminal cytosolic domain and a COOH-
terminal catalytic domain. Black triangles represent N-glycosylation sites. Black 
boxes indicate the sialyl motifs: large (L), short (S), motif III (III), and very short 
(VS) that are conserved in all mammalian sialyltransferases). (C) The overview 
of the polyST enzyme mRNA level during mouse brain development studied by 
quantitative real-time RT-PCR using whole mRNA extracts from the brain. 
Adapted from (Schnaar et al., 2014) 
Figure 1.4: Presentation of polysialyltransferase enzymes. 
(B) 
(C) 
(A) 
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1.6.3 Polysialylated NCAM 
The most common modification of membrane secreted proteins and glycan 
residues is glycosylation, which plays an important role in protein folding, 
stability and function (Varki, 1993). This is true for NCAM, which is particularly 
subject to post-modification by polySia, expressed predominately during the 
embryonic development stage. NCAM glycosylation occurs in the endoplasmic 
reticulum (ER) and Golgi apparatus (for details, see review (Kiss and Rougon, 
1997). Polysialylated-NCAM (polySia-NCAM) plays an important role in neural 
development and plasticity (Rutishauser and Landmesser, 1996, Kiss and 
Rougon, 1997, Jensen and Berthold, 2007).  
In organogenesis, polySia is expressed in mesodermal and endodermal 
derivatives; NCAM doesn‟t carry polySia at this time. On the embryonic (E) day 
8-8.5 in mice, NCAM is polysialylated later in the prenatal phase until E9 when 
all NCAM is polysialylated, reviewed in (Hildebrandt et al., 2010, Bonfanti, 2006, 
Brocco et al., 2003). Within week 1, the expression of polySia decreases, 
NCAM isoforms NCAM-140 and NCAM-180 appear without polySia whereas 
NCAM-120 appears during the postnatal regulation of the brain (Hildebrandt et 
al., 2010).  
In the developing brain, NCAM is highly polysialylated and found abundantly 
(Angata and Fukuda, 2003). This results in NCAM having various roles in 
promoting cell adhesion, cell migration, neurite outgrowth, branching, neuronal 
path finding and synapse formation (Bonfanti, 2006, Brusés and Rutishauser, 
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2001, Gascon et al., 2007, Kiss and Rougon, 1997, Rutishauser and 
Landmesser, 1996). 
Polysialylated NCAM is also constantly present, albeit at significantly lower 
levels in restricted areas of the brain, which are the olfactory bulb and 
hippocampus, where the neural generation and plasticity persist (Angata and 
Fukuda, 2003, Rutishauser and Landmesser, 1996). PolySia‟s role in cell-cell 
interaction has been revealed using the NCAM deficient mice and endo-N 
treatment, which covered the requirement for polySia for olfactory neuroblast 
migration (Angata and Fukuda, 2003, Cremer et al., 1994). These indicate the 
role of NCAMs in the regeneration and the development of neural cells.  
1.6.4 PolySia functional roles and its cellular interactions 
Various in vitro and in vivo studies (knockdown mice of polySia/NCAM) give 
evidence of several roles of polySia in cell interactions reviewed in (Gascon et 
al., 2007, Hildebrandt et al., 2010, Schnaar et al., 2014, Rutishauser, 2008, 
Hildebrandt et al., 2007). PolySia has a negative charge and the attachment of 
polySia on NCAM increases the hydrodynamic radius, which causes an 
increase in the intermembrane space and disrupts the adhesion properties of 
NCAM (Figure 1.5A) (Brusés and Rutishauser, 2001, Fujimoto et al., 2001, 
Johnson et al., 2005). In the case of polySia removal, using endo-N results firm 
binding between two NCAM molecules (Hoffman and Edelman, 1983, Sadoul et 
al., 1983).  
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Figure 1.5: Different modes of polySia cell interactions. 
(A) PolySia shields neural cell adhesion molecule (NCAM) and removal of polySia induces NCAM homo- or hetero-signalling. (B) 
PolySia acts as a negative regulator preventing NCAM interaction with other molecules (integrin). (C) PolySia initiates the interaction of 
cell surface receptors (brain-derived neurotrophic factor with TrkB) by acting as a scavenger molecule. (D) PolySia also inhibits NCAM 
signalling or (E) polySia binding to other cell surface or cell matrix molecules (glycosaminoglycans). (F) PolySia modules ac tivation of 
ionotropic glutamate receptors or formation of NCAM signalling complexes formation (G). Modified from (Hildebrandt et al., 2007). 
(A) (D) (C) 
(B) (F) (E) (G) 
CHAPTER ONE 
 
 
 
28 
 
The presence of polySia on NCAM regulated NCAM-mediated adhesion, which 
prevents cell contacts, suggesting the impact of polySia on neurite outgrowth. 
Study of polySia negative mouse models has revealed that the important role of 
polySia is to shield NCAM and is associated with the organisation, timing and 
site-specificity of NCAM interactions (Hildebrandt et al., 2007). The role of 
polySia in NCAM adhesion has been proposed, which is that it causes a steric 
inhibition of cell to cell apposition ((Rutishauser and Landmesser, 1996); 
Figure1.5B). This model suggests that the charge and the hydration nature of 
polySia hinder NCAM interactions either with NCAM or with other molecules 
including integrins (Fujimoto et al., 2001, Johnson et al., 2005, Yang et al., 
1994). The removal of polySia allows cell interaction and has been widely 
studied using polySia and NCAM mouse models and also the impact of polySia 
on fasciculation, branching and axons (Rutishauser and Landmesser, 1996, 
Weinhold et al., 2005). 
Besides this, there is considerable evidence for the role of polySia in the 
developing nervous system. The presence of polySia on the neurons of the 
hippocampus and hypothalamus becomes more sensitive to brain-derived 
neurotropic factors, which gives the indirect explanation of the role of polySia as 
a scavenger molecule (Figure 1.5C) or polySia inhibiting the NCAM cis-
interaction (Figure 1.5D) (Hildebrandt et al., 2007). Therefore, loss of polySia 
promotes NCAM formation (Figure 1.5 A, B) or modulates NCAM cis-
heterophilic interactions, however further experimental validation for these 
proposed models is required (Kiselyov et al., 2005). 
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NCAM is not only an adhesion molecule but also plays a role in intracellular 
signalling. NCAM functions in a Ca2+-independent manner and mediates cell-
cell (homophilic (NCAM-NCAM), heterophilic (NCAM-fibroblast growth factor 
receptor (FGFR)) and cell-matrix interactions in the cell (including neural) 
(Gascon et al., 2007, Kiryushko et al., 2006). The NCAM crystal structure 
reveals the involvement of Ig1 and Ig2 in cis interactions (same cells) whereas 
Ig3 mediates the NCAM trans interactions (opposing cells), which 
instantaneously binds to Ig1 and Ig2 forming a zipper like NCAM adhesion 
complex (Soroka et al., 2003). These interactions activate the intercellular 
responses which are cell differentiation, growth, survival and many other cellular 
mechanisms (Soroka et al., 2003).  
Nearly twelve years ago, the functions of NCAM with FGFR was suggested to 
induce neurite outgrowth (Kiselyov et al., 2005). Several studies suggested 
polysialylation of NCAM stimulates FGFR dimerization upon binding. This 
activates several proteins resulting in various downstream signalling pathways 
(Walsh and Doherty, 1997). Mouse models have shown the role of polySia 
affecting NCAM interactions whereas neuroblastoma cells without polySia 
promote NCAM trans-interaction at cell contact sites by reducing proliferation 
and result in the activation of the extracellular signal-regulated kinase (ERK) 
pathway (Seidenfaden et al., 2003). 
Studies of neuroblastoma cells and the subventricular zone (SVZ) derived 
interneuron precursors which demonstrated the role of polySia-regulated and 
ERK1/2-dependent heterophilic signalling results in neuronal differentiation and 
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survival of neuroblastoma cells (Seidenfaden et al., 2003, Seidenfaden et al., 
2006). Similar findings were found in in vivo studies with polySia removal by 
endo-N stimulating neuronal differentiation of SVZ derived precursors in explant 
cultures and in situ (Petridis et al., 2009). 
In addition, loss of polySia reduced cell motility and enhanced focal adhesion of 
tumour cells. In both cases, effects occurred in an NCAM-dependent manner 
(Eggers et al., 2011). 
NCAM homophilic interactions also stimulate neurite extension (Rønn et al., 
1998) and play an important role during development through changes in 
NCAM expression (Rutishauser and Landmesser, 1996). Several studies 
indicate the role of NCAM in learning and memory, especially the post-
translationally modified NCAM by polySia in the adult brain, which have been 
shown to be associated with learning (Rønn et al., 1998). 
Cancer cell function is affected by NCAM signalling, for example, transfection of 
rat glioma cell line (BT4Cn) with human NCAM-140 significantly reduced tumour 
invasiveness in vivo and the expression of NCAM in pancreatic β-cell tumour 
abolished the metastasis formation (Edvardsen et al., 1994, Perl et al., 1999). 
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1.6.5 Clinical expression of polySia in cancer 
Different expression of sialylated phenotypes has been employed to 
differentiate between benign and malignant tumours (Ivan Martinez-Duncker, 
2011). Studies have suggested a role for polySia whereby polySia-NCAM 
modulates tumour cell adhesion and facilitates cell detachment, the first stage 
of the metastatic cascade.  
The expression of polySia has been shown to correlate with tumour 
progression, metastasis and invasion in metastasis-prone malignant tumours, 
including neuroblastoma, glioma, rhabdomyosarcoma, small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC), as summarised in Table 1.3. 
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Table 1.3: In vitro evidence of the role of polysialylated NCAM in tumours. 
Tumour name No. of 
patients 
PolySia 
expression (%) 
PolySia-NCAM relation with tumour Reference 
Neuroblastoma 24 63 Diagnosis and prognosis marker (Glüer et al., 1998b) 
136 100 STX mRNA clinical utility as a molecular marker (Cheung et al., 2006) 
5 60 Marker for differential diagnosis (Glüer et al., 1998a) 
36 58 PolySia-NCAM is a significant molecular marker (Korja et al., 2009) 
     
Astrocytoma 30 100 Highly malignant astrocytoma express more polySia (Petridis et al., 2009) 
     
Rhabdomyosarcoma 11 100 PolySia-NCAM as a diagnostic and prognostic marker (Gluer et al., 1998c) 
     
Wilm’s 25 100 Onco-developmental antigen (Roth et al., 1988b) 
9 100 Onco-developmental antigen (Roth et al., 1988c) 
5 100 PolySia-NCAM is an onco-developmental antigen in kidney (Roth et al., 1988a) 
2 100 useful marker for differential diagnosis (Glüer et al., 1998a) 
     
 
Small cell lung 
cancer (SCLC) 
17 60 NCAM with polySia as a prognostic factor (Miyahara et al., 2001) 
70 93 NCAM-polySia expression could favour metastatic spread (Lantuejoul et al., 1998) 
25 100 PolySia can be used to distinguish two neuroendocrine lung tumours (i.e. 
SCLC and carcinoids) 
(Komminoth et al., 1991) 
50 100 High polySia expression correlates with reduced cell-cell adherence and 
metastasis 
(Scheidegger et al., 1994) 
     
Non-small cell lung 
cancer (NSCLC)* 
57 49 PolySia and STX as a clinical marker (Tanaka et al., 2000) 
236 19 clinical marker (Tanaka et al., 2001) 
Other lung cancer 50 72 Poor differentiation and aggressive clinical behaviour (Lantuejoul et al., 1998) 
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Tumour name No. of 
patients 
PolySia 
expression (%) 
PolySia-NCAM relation with tumour Reference 
Glioma 30 30 PolySia facilitates tumour invasion of glioma in the brain 
 
(Suzuki et al., 2005) 
Glioblastoma (GBM) 56 70 PolySia-NCAM represents a valuable biomarker for the prognosis of GBM 
patients 
(Amoureux et al., 2010) 
     
Medulloblastoma 29 100 PolySia-NCAM a new biologic marker (Figarella-Branger et al., 
1996) 
     
Nephroma 8 38 Renal onco-developmental marker (Nadasdy et al., 1993) 
     
Medullary thyroid 33 100 PolySia of NCAM is a valuable marker to distinguish medullary carcinomas 
from other types of thyroid carcinomas 
(Komminoth et al., 1994) 
     
Pancreatic 15 67 Expression correlates with tumour proliferation and invasion (Kameda et al., 1999) 
     
Multiple myeloma 70 80 Valuable marker for monitoring therapy (Kaiser et al., 1994) 
92 61 Tumour prognostic marker (Smith et al., 1996) 
     
Colorectal cancer 39 87 Importance of polysialylated NCAM in tumour development (Fernández-Briera et al., 
2010) 
     
Pituitary tumours 82 46 Polysialylated NCAM is strongly related to tumour invasion (Trouillas et al., 2003) 
 12 36 Prognostic factor for pituitary tumours (Wierinckx et al., 2007) 
     
 
*(carcinoids, atypical carcinoids, and neuroendocrine carcinomas) 
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Many studies have focused on trying to understand the role of the polysialylated 
NCAM in neuroblastoma (Glüer et al., 1998a, Glüer et al., 1998b, Hildebrandt et 
al., 1998). Neuroblastoma is highly malignant and in metastatic childhood 
cancer it has been reported that most neuroblastoma express on NCAM-180 
(Winter et al., 2008). Therefore, polySia-NCAM is considered as an onco-
developmental antigen which is expressed not only in other malignant neuro-
dermal and neuroendocrine tumours but also in neuroblastoma (Hildebrandt et 
al., 1998).  
Polysialylated NCAM expression was studied in neuroblastoma patients 
showing high level of polySia-NCAM in advanced clinical stages of the disease 
and this result was correlated with other neuroblastoma prognostic factors 
including MYCN gene amplification and serum concentrations (Glüer et al., 
1998b). In addition to this, the serum levels correlated with the polysialylated 
NCAM contents of the neuroblastoma and thus is a useful prognostic and 
diagnostic neuroblastoma marker (Gluer et al., 1998d). 
Furthermore, neuroblastoma cells treated with endo-N showed a significant 
reduction in cell migration, indicating the impact of polySia removal on the 
progenitor cell biology (Petridis et al., 2009). Studies have illustrated the 
presence of polySia promoting migration in neuroblastoma and 
rhabdomyosarcoma cells, providing evidence for the initiation of NCAM 
interaction when polySia is removed and this was consistent with the in vitro 
studies (Eggers et al., 2011). 
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It has previously been mentioned that polySia synthesis is carried out by PST 
and STX whereas STX mRNA expression has been reported to be a potential 
molecular marker of metastatic neuroblastoma (Cheung et al., 2006). STX has 
been described as a novel molecular marker to detect tumours and is thought to 
be a key regulator of synthesis polySia in tumours. In particular, transfection of 
C6 glioma cells with STX in rats showed an increase in polySia expression 
promoting invasion to the corpus callosum when inoculated into the brain, which 
was rarely seen in mock-transfected C6 cells describing the close correlation of 
polySia and tumour invasion (Suzuki et al., 2005).  
PolySia re-expressed in malignant tumours e.g. Wilm‟s tumour, has been 
reported first and studied using anti-monoclonal polySia antibody (mAb 735), 
which described the presence of polySia on NCAM as an „onco-developmental 
antigen‟ (Fernández-Briera et al., 2010, Roth et al., 1988c).  
Daniel et al (2001) injected endo-N into mice with tumours strongly expressing 
polySia-NCAM, this showed a decrease in polySia expression and established 
the relationship between polySia expressed in the tumour cells and metastasis. 
Similar work was studied on different subsets of cells with different phenotypes 
found that polySia positive tumour cells produced more intracutaneous 
metastasis that low expressing polySia cells when nude mice was injected 
subcutaneously (Scheidegger et al., 1994). 
Polysialylated NCAM is considered a prognostic factor in lung cancers (both 
small cell and non-small cell) where Trouillas et al (2003) analysed the 
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polysialylated NCAM expression in 82 pituitary tumours and found 
polysialylated NCAM in 42.3% of typical pituitary tumours and also these 
tumours were endoN sensitive and suggested a strong correlation with tumour 
invasion. Furthermore, two studies carried out with non-small cell lung cancers 
demonstrated the clinical significance of polySia, especially the presence of the 
polyST enzyme STX, which is associated with the clinical development and 
could be used potentially either as a clinical marker or new cancer therapeutic 
target (Tanaka et al., 2001, Tanaka et al., 2000).  
PolySia expression is also seen in other neuroendocrine lung tumours where 
polySia expression is associated with higher stages of disease. 17 surgically 
SCLC specimens were studied using immunohistochemistry and showed 60% 
polysialylated NCAM expression, whereas other studies showed 93% polySia 
expression in 70 SCLC tumours suggesting the NCAM-polySia is regarded as a 
prognostic factor in SCLC tumours (Lantuejoul et al., 1998, Miyahara et al., 
2001). Altogether, clinical expression of polysialylated NCAM in various tumours 
functions as an onco-developmental antigen. This expression of polySia 
contributes to tumour cell detachment, tumour growth, invasion and finally to 
metastasis.  
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1.6.6 STX inhibition by biochemically engineered sialic acids 
PolySia is ectopically expressed in tumours and is thought to be playing a role 
in tumour invasion as described in previous sections. The expression of STX is 
thought to be responsible for NCAM polysialylation in tumours. Hence, inhibiting 
polySia synthesis can be an anti-tumour agent against these tumours. One 
approach demonstrated by Bertozzi‟s group that treating cells with sialic acid 
precursor molecules i.e. N-butylmannosamine. This precursor inhibited the 
polysialyltransferases activity and can be applied to polySia expressing tumours 
especially neuroblastoma can be potentially treated with the modulation of 
polysialylated NCAM by altering polySia expression (Mahal et al., 2001). Also, 
novel sialic acid precursors, N-propanoyl mannosamine (ManNProp) cause 
selective inhibition of STX driven by polysialylated NCAM (Horstkorte et al., 
2004a). 
Recently, investigations have been carried out using the epilepsy therapy drug 
known as Valproic acid (VPA, 2-propylpentanoic acid), which showed a link with 
anti-cancer activity. It is shown that VPA treatment results in metastatic down-
regulations of tumour cells in different experimental conditions and depends on 
NCAM modulation (Bork et al., 2007). Work done by Beecken et al (2005) 
showed RT-PCR results that VPA up-regulates PST and down-regulates STX at 
mRNA levels. In this study, small molecule polyST inhibitors have been 
employed and their effect on polySia has been studied, in reflection to cell 
functions (particularly invasion) and more details are given are chapter 4.   
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1.7 Aims and objectives 
Tumour dissemination (adhesion, migration and invasion) is the main cause of 
the failure of cancer therapy resulting in high mortality. Thus, there is much 
interest in developing therapeutic strategies which can control tumour 
dissemination. 
As has been reviewed here, expression of polySia on NCAM reduces the 
adhesiveness of tumour cells and promotes tumour dissemination. This is 
strongly related with poor clinical prognosis and correlates with tumour 
aggressiveness and invasion in neuroblastoma and several other tumours. 
Thus it is hypothesised that by targeting the expression of polySia (i.e. by 
removal/reduction) it should allow control of tumour dissemination. One way of 
doing this is by inhibiting polySia synthesis in the first place by developing 
inhibitors of the enzyme. This will in turn reduce cell-surface expression of 
polySia found on cancer cells, increasing cell-cell and cell-matrix adhesion, and 
thus reduce the opportunity for tumour cell dissemination. This strategy has 
been adopted at the Institute of Cancer Therapeutics (ICT), where small 
molecule inhibitors of polyST are being designed and synthesised.  
In this project, the aims are to establish specific in vitro tests to evaluate these 
new molecules in a panel of characterised cell lines.  
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These aims will be achieved by addressing the following objectives: 
 Assembly and characterisation of a panel of tumour cell lines having a 
range of polySia and polyST expression, in terms of growth parameters 
and expression of polySia and other sialic acids. 
 Development and validation of in vitro assays to assess the effects of 
polyST inhibition on polySia decoration of NCAM and on cell invasion in 
both 2D and 3D models.   
 Screening and evaluation of the potential effect of novel inhibitors of 
polyST developed „in-house‟ on the inhibition of polySia expression and 
tumour cell invasion. 
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CHAPTER TWO 
 
 
2 Assembly and characterisation of a cell line panel for 
screening polySTi 
2.1 Introduction 
As reviewed in Chapter 1, in high-risk neuroblastoma patients, the overall 
survival rate is poor. Despite new advances in treatment, relapse is the biggest 
obstacle to successful therapy. As previously described, the expression of 
polysialylated NCAM correlates with neuroblastoma prognostic and diagnostic 
markers (Table 1.3). Therefore, the strategy proposed here is that by 
developing synthetic inhibitors of polyST (STX), this will reduce neuroblastoma 
progression and metastasis. One of the major aims of neuroblastoma treatment 
is to develop therapies targeting the cancerous cells. For that reason, the 
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selection of suitable relevant and validated models is highly important for the 
evaluation of novel drugs.  
The screening panel should include cells expressing the molecule(s) of interest, 
ideally at different levels i.e. high, medium, low or null. In this case, the 
molecules of interest are polySia and two polyST enzymes (PST and STX). For 
this study, five cancer cell lines were selected for investigation based on 
previous studies both from the literature and in-house. There are no specific 
antibodies available that can detect polyST. However, previous studies have 
shown a direct association between polySia with polyST expression 
(Hildebrandt et al., 1998). Therefore, the effect of inhibition of the enzyme can 
be detected by monitoring polySia expression. For this investigation, a mixture 
of naturally expressing cell lines and isogenic lines were selected for the 
screening of polySia expression. 
A pair of isogenic rat glioma cells were utilised here where the only difference is 
that one has been engineered to express polyST enzyme (i.e. STX) (Suzuki et 
al., 2005) and as a consequence result in polySia expression. Isogenic cells 
display high genetic similarity with a unique feature (Bajaj et al., 2009). They are 
useful as they are able to distinguish and exploit the difference between polySia 
expression shown in house and in the literature. 
As neuroblastoma is the cancer of interest, two human neuroblastoma cell lines 
IMR-32 and SH-SY5Y have been selected, which are polyST, polySia and 
NCAM positive; this is based on earlier studies (Valentiner et al., 2011, Al-
Saraireh et al., 2013). Previously, high levels of polySia and STX expression in 
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C6-STX and IMR-32 were shown compared to SH-SY5Y, whereas PST levels 
were barely detected in IMR-32 cells only (Al-Saraireh et al., 2013).  
Finally, the colorectal adenocarcinoma cell line DLD-1, was studied as a 
negative control. These cells do not express polyST, polySia or NCAM as 
revealed previously (Jimbo et al., 2001, Al-Saraireh et al., 2013). 
Various tools for studying polySia expression have been described in the 
literature. Functional methods to study polySia related to this study include, 
endoneuraminidase N (endo-N), anti-polySia antibodies and endo-N-GFP, and 
their interactions with polySia is shown in Figure 2.1.  
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Figure 2.1: Tools for the study of polySia. 
PolySia is detected by anti-polySia antibody, endo-N and endoN-GFP. (Endo-N: 
Endoneuraminidase; GFP: Green Fluorescent Protein). Modified from 
(Rutishauser and Landmesser, 1996). 
Anti-PolySia 
Endo-N/EndoN-GFP 
n = 8 - 100 
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Endo-N has been used as a biological probe for specific and rapid degrading of 
α-2,8-glycosidically linked polymers of sialic acid (i.e. polySia) with a chain 
length not less than seven to nine residues (Finne and Mäkelä, 1985, 
Rutishauser et al., 1985). This enzyme has been shown to recognise and 
specifically remove polySia from the rat neonatal neural membrane (Vimr et al., 
1984). Endo-N treatment has been used to reduce expression of polySia in vitro 
and in vivo in order to understand the structural and functional properties of 
polySia in the regulatory process of cell migration, cell adhesion, neurite 
outgrowth, branching, axon path-finding and synapse formation (Angata and 
Fukuda, 2003). For that reason, endo-N is a useful tool to study direct or 
indirect degradation of polySia in various conditions and assays including 
removal of polySia from living cells and analysing the recovery of polySia re-
expression (Chapter 3; (Al-Saraireh et al., 2013)).  
Relatively few anti-polySia antibodies have been reported for the detection of 
polySia as shown in Table 2.1. First is the H.46 antibody used for the detection 
of polySia, following endo-N treatment (Vimr et al., 1984). Other commonly 
used antibody is mAb 735 raised in NZB nude mice against B meningococcal 
antigen and binds to polySia with eight or more residues (Frosch et al., 1985). 
Earlier studies have shown the use of H.46 and mAb 735 for polysialylated 
NCAM characterisation (Frosch et al., 1985, Livingston et al., 1988, Vimr et al., 
1984). Other mouse monoclonal antibodies are mAb OL.28, mAb 2-4B and 
mAb 2-2B, which have been used for the identification of polySia in various 
cancer cell lines are listed in Table 2.1.  
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In this thesis, anti-polySia antibody (mAb 735) has been used. The specificity of 
mAb 735 has been extensively characterised in previous studies (Frosch et al., 
1985). MAb 735 does not strictly favour the recognition of polySia chains 
forming extended helices but has a high affinity to recognise longer polySia 
chains i.e. every three sialic acids units in a paired manner (Husmann et al., 
1990, Nagae et al., 2013). Therefore, it considered a specific probe for the 
definite polySia detection. 
Another polySia recognising probe was developed in which bacteriophage-
derived endo-sialidase was catalytically inactive and fused to green fluorescent 
protein (GFP). This construct binds to polySia but does not possess catalytic 
activity (i.e. it does not cleave polySia). This construct can be used as an 
alternative to the anti-polySia antibodies. EndoN-GFP is a single step labelling 
tool which has high specificity for polySia (Jokilammi et al., 2004). Studies have 
shown that both endoN-GFP and mAb 735 have the same labelling pattern and 
both have been used to characterise neuroblastoma tissues (Jokilammi et al., 
2004, Korja et al., 2009). 
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Table 2.1: List of anti-polySia antibodies and their features. 
Antibody Monoclonal 
(Mono)/  
polyclonal (poly) 
Type (Ig) Source PolySia chain 
recognition 
Antigen species Degree of 
polymerisation 
Reference 
H.46 Poly IgM Horse Sia/Neu5Gc Meningitidis Group 
B bacteria 
≥8 (Allen et al., 1982) 
(Sato et al., 1995) 
735 Mono IgG Mouse Sia/Neu5Gc Meningitidis Group 
B bacteria 
≥8 (Frosch et al., 
1985) (Sato et al., 
1995) 
12E3 Mono IgM Mouse Sia Embryonic rat 
forebrain 
≥5 (Sato et al., 1995) 
OL.28 Mono IgM Mouse Sia Rat 
oligodendrocytes 
≥4 (Martersteck et al., 
1996) 
2-4B Mono IgM Mouse Neu5Gc Autoimmune mice 
 
≥2 (Sato et al., 1998) 
2-2B Mono IgM Mouse Sia Meningitidis Group 
B bacteria 
≥3 (Rougon et al., 
1986) 
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As described in Chapter 1, it is important to establish selectivity of polyST 
inhibitors. There is a chance that polyST inhibitors may lack total selectivity, 
thereby inhibiting α-2,3 and α-2,6-STs. This is significant since sialylation is 
carried out by twenty different sialyltransferases, which catalyse the different 
glycosidic linkages through α-2,3- or α-2,6- bonds to galactose, N-
acetylgalactosamine or α-2,8-bonds to other molecules resulting in polySia as 
mentioned in section 1.6.2 (Harduin-Lepers et al., 2012).  
Sialic acids play extensive roles in physiological and pathological processes, 
including cancer, immune response regulation and pathogen binding (Varki and 
Varki, 2007). For example α-2,3 sialic acid is involved in myelin formation and 
maintenance (Kleene and Schachner, 2004). Two recognition molecules, L1 
(immunoglobulin superfamily) and CD24 (a highly glycosylated mucin type 
glycoprotein) work cooperatively in neurite outgrowth and signal transduction 
pathway, and the binding of or inhibition of neurite outgrowth (Kleene et al., 
2001).  
In addition, these sialic acids also play a significant role in pathological 
processes. For example, α-2,3 sialic acid is the main glycan involved in H5N1 
„bird flu‟ virus and humans have resistance to this infection due to the display of 
α-2,6 sialylated glycans on the epithelium of the upper respiratory tract (Varki 
and Varki, 2007). Aberrant expression of a-2,6-ST has also been reported in 
many human malignancies, whereby expression of ST6GAL1 gene is found in 
colon, breast and cervical cancers, acute myeloid leukaemia and some brain 
tumours reviewed in (Dall'Olio and Chiricolo, 2001).  
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There are various methods available which can be used to detect and identify 
various linkages by which sialic acids are joined together to generate diversity 
(Varki, 2007, Knibbs et al., 1991). This includes plant lectins, antibodies, 
recombinant soluble microbial proteins and recombinant soluble mammalian 
receptors as reviewed in (Varki and Varki, 2007).  
Lectins have specificity for linkages (e.g. α-2,6 sialic acids are recognised 
specifically by SNA) and can distinguish between N-glycans and O-glycans 
(Cumings et al., 2009) unlike antibodies or other methods. Furthermore, tumour 
associated carbohydrates may express at a low or high level which cannot be 
determined by other techniques. For this, lectins are a useful tool to investigate 
the expression of sialic acids in a panel of tumour cells. For that reason, in this 
thesis, plant lectins are used to determine the specificity and distribution of 
native sialic acids, and the linkages of target cells at the cell surface. The 
information derived from lectins gives an indication of polySTi specificity.  
The plant lectins are glycan-binding proteins and have been used as a powerful 
tool to study glycan structures (Sharon and Lis, 2004). The term lectin is derived 
from the Latin word legere meaning „select‟ or to „choose‟, and has been 
generalised to include all non-immune carbohydrate-specific agglutinins 
regardless of source or blood-type specificity (Sharon and Lis, 2004). Lectins 
were initially found in plants but later they were isolated from microorganisms 
and animals (Sharon and Lis, 2004). They are involved in recognition of various 
biological processes including metastasis, inflammation, host-pathogen 
interactions and exploring carbohydrates structures (Sharon and Lis, 2004). 
Several lectins have been reported which interact with sialic acids. The lectin 
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from elderberry bark and two isoform of Maackia amurensis seeds Maackia 
amurensis I lectin (MAL I) and Maackia amurensis II lectin (MAL II) have been 
used extensively in thesis to detect α-2,6 and α-2,3 sialic acids (Knibbs et al., 
1991, Konami et al., 1994, Shibuya et al., 1987). These lectins have their own 
specific specificity and therefore provide useful information regarding the effect 
of polySTi on other linkages.  
Before utilising these assays for screening polySTi, these sialic acid labelling 
tools need to be validated, and this was achieved using a known polySTi: 
Cytidine monophosphate (CMP). CMP has been used previously as a tool 
compound, entering the Golgi apparatus to compete with CMP-Sia, inhibit 
polyST and thus polySia synthesis. This has been predicted as a rate-limiting 
step by the earlier studies (Miyazaki et al., 2008). However, CMP is not likely to 
be a successful drug, since CMP is hydrophilic and charged at physiological pH. 
High concentrations of CMP (i.e. mM) are required to enable sufficient 
compounds to cross the hydrophobic cell membrane. CMP has been 
successfully used in-house and in the literature as a useful tool compound, 
effectively reducing tumour cell-surface polySia expression and cell migration 
(Al-Saraireh et al., 2013). 
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2.1.1 Aims & Objectives 
In this chapter, a panel of cell lines which will be suitable for the study of the 
effects of polyST inhibitors (polySTi) will be assembled and characterised in 
terms of growth parameters and expression of polySia, NCAM and other sialic 
acids. These aims will be addressed by pursuing the following objectives: 
 Characterisation of the cell growth parameters for each cell line using the 
MTT assay in order to optimise seeding densities for further experiments 
 Characterisation of polySia expression in the panel 
 Validation of the polySia labelling tools using a known polySTi CMP 
 Determination of the distribution of other sialic acids (α-2,3 and α-2,6) in 
panel of cancer cell lines and validation with CMP using lectin labelling 
technique   
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2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Reagents and Solutions 
All cell culture reagents and general chemicals were from Sigma-Aldrich (Poole, 
UK) unless otherwise stated. 
Tissue culture dishes, flasks, and plasticware were purchased from Corning 
(Corning Amsterdam, Netherlands). 
2.2.1.2 Probes and enzymes 
Vectashield hardset fluorescent mounting medium with 4,6-Diamidino-2-
phenylindole (DAPI) was purchased from Vector Laboratories Ltd 
(Peterborough, UK). 
Endoneuraminidase-green fluorescent protein (endoN-GFP) was kindly 
provided by Professor Jukka Finne (University of Helsinki, Helsinki, Finland), 
and was stored at 4°C in the dark.  
Monoclonal mouse IgG anti-polySia (mAb 735, clone 2) was kindly gifted by 
Professor Rita Gerardy-Schahn (Hannover Medical School, Germany). The 
polyclonal rabbit anti-mouse antibody conjugated with tetramethylrhodamine 
isomer R (TRITC) was purchased from Dako (Cambridgeshire, UK). 
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Polyclonal Rabbit anti-NCAM (ab5032) and Fluorescein isothiocyanate (FITC) 
conjugated goat anti-rabbit secondary antibodies were purchased from Millipore 
(UK) and Molecular Probes (UK) respectively.  
All normal sera were purchased from Vector Laboratories (Peterborough, UK). 
The specificity of the polySTi was determined using the sialic acid recognising 
lectins from elderberry bark, Sambucus nigra agglutinin (SNA/EBL) to detect α-
2,6 sialic acid, and two from the legume tree Maackia amurensis leukoagglutinin 
(MAL/MAL I) or Maackia amurensis hemagglutinin (MAH/MAL II) to detect and 
α-2,3 sialic acid. Biotinylated MAL II (MAH), FITC-conjugated SNA and MAL I 
and fluorescent avidin kit were obtained from Vector Laboratories Ltd 
(Peterborough, UK) unless otherwise specified. 
Cytidine monophosphate (CMP) was prepared using complete medium. CMP 
was obtained from Sigma-Aldrich (Poole, UK).  
2.2.2 Cell lines 
Human neuroblastoma cells (IMR-32 and SH-SY5Y) and colon cells (DLD-1) 
were obtained from American Type Culture Collection (ATCC, Manassas, USA). 
The glioma cell lines (C6-STX and C6-WT) were kindly provided by Prof. Minoru 
Fukuda (Sanford-Burnham Institute, USA). 
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2.2.3 Mammalian cell culture techniques 
2.2.3.1 Cell culturing conditions 
IMR-32 cells were grown and maintained in tissue culture treated dishes (100 
mm x 20 mm) (Corning, Netherlands) containing Minimum Essential Medium 
Eagle medium with non-essential amino acids supplemented with 10% (v/v) 
fetal bovine serum (FBS), 2 mM L-glutamine, and 1 mM sodium pyruvate to 
form complete growth medium. All the other cell lines were maintained in 75 
mm2 cell culture treated flasks (T-75) (Corning, Netherlands).  
The glioma cell lines C6-WT and C6-STX were grown and maintained in Alpha 
Minimum Essential medium (VWR, Leicestershire, UK) supplemented with 10% 
(v/v) FBS.  
SH-SY5Y cells were grown to 1:1 mixture of Minimum Essential Medium Eagle 
with non-essential amino acids and Nutrient Mixture F-12 Ham supplemented 
with 10% FBS, 2 mM L-glutamine and 1 mM sodium pyruvate. DLD-1 cells were 
grown and maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% FBS, 2 mM L-glutamine and 1 mM sodium pyruvate.  
All cell lines were incubated at 37°C, 5% CO2 in a humid atmosphere. On 
reaching 70-80% confluency, cells were passaged and medium was changed 
after 3-4 days. All cell lines were routinely checked for mycoplasma 
contamination using a Mycoplasma Detection ELISA Kit purchased from 
RnDSystems (Oxfordshire, UK).  
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2.2.3.2 Preparation of single cell suspension 
When cells reached 70% confluence, cell culture medium was removed, and 
cells were washed twice with Hank‟s Balanced Salt Solution (HBSS) and 
harvested using 0.25% Trypsin/EDTA solution. Cells were incubated with 
trypsin for several minutes at 37°C until they began to detach. Once cells were 
fully detached, complete medium was added to neutralise the solution which 
was then centrifuged for 5 min at 1000 rpm.  
The supernatant was removed and cell pellet was re-suspended in 10 ml of 
fresh complete medium. Cell were counted using Neubauer improved bright line 
haemocytometer (VWR, Leicestershire, UK) with an inverted phase contrast 
microscope (Olympus CK-2, x20 objective lens magnification). The 
haemocytometer and the coverslips were cleaned with 70% ethanol. The 
cleaned coverslip was placed over the wells of haemocytometer. A small 
volume of cell suspension (10 µl) was added at the edge of two chambers of 
haemocytometer and allowing fluid to go underneath the coverslip. Cells were 
counted in 5 squares of each chamber and an average was taken. Therefore, 
cell concentration per ml is calculated using the following equations:  
No. of cells (cells/ml)   =   average no of cells x dilution factor x 104 
Cell counts were adjusted to the required concentration by the addition of the 
medium and then transferred into a new flask or a petri dish containing fresh 
medium. 
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2.2.3.3 Growth curves using the MTT assay 
Growth curves were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, which used to detect cell viability and 
evaluate the metabolic activity of cells (Mosmann, 1983).  
Cells were harvested from their exponential phase. Seeded densities between 
100-100,000 cells/ml was added in 200 μl medium in round bottom 96-well 
plates and incubated overnight at 37°C, 5% CO2 in a humid atmosphere. 
Briefly, MTT stock solution (5 mg/ml: Sigma-Aldrich) was prepared by dissolving 
100 mg of MTT in 20 ml of Ultrapure water, passing through a 0.2 µm filter and 
storing at 4°C in the dark. MTT working solution (1:10 dilution) was prepared in 
complete medium and 200 µl of the MTT solution was added to the wells, each 
plate containing blank wells (without cells) and sample wells (with cells). 
Following a 4 h incubation time with the MTT at 37°C, 5% CO2, the supernatant 
removed and 150 µl of dimethyl sulphoxide (DMSO) added, to dissolve the 
formazan crystals. The absorbance was read at 540 nm using Thermo 
Labsystems Multiskan Plus Microplate reader (Thermo Labsystems, UK).  
From the data, the mean absorbance was calculated for each cell 
concentration, by subtracting the mean background absorbance from the mean 
absorbance of sample wells. A graph of time in cultures (days) was plotted 
against mean absorbance to generate the growth curves. All samples were 
analysed in triplicate. 
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2.2.4 Detection of the neural cell adhesion molecule (NCAM) using 
immunocytochemistry 
Upon 70% cells confluency, cells were trypsinized as described in section 
2.2.3.2. Cell number was adjusted (1x104 to 1x105 cells/ml) and seeded onto 
autoclaved 22x22 mm glass coverslips in a six-well plate in 1 ml medium. The 
plates were incubated overnight at 37°C in a 5% CO2 atmosphere. All 
experimental steps were carried out at room temperature except where stated. 
Once cells had adhered, the coverslips were rinsed twice with HBSS and fixed 
with ice cold methanol at -20°C (30 min) or 4% PFA (15 min at room 
temperature). The fixative was removed and slides were allowed to dry. Fix 
cells either used directly for immunolabelling experiments or stored at with -
20°C. The optimised conditions were achieved by using different fixatives and, 
different concentrations of primary and secondary antibodies.  
NCAM expression was characterised using immunochemistry. Briefly, cells 
were incubated with different concentrations of anti-NCAM polyclonal antibody 
prepared in phosphate buffered saline (PBS) for 30 min at room temperature. 
Then, the coverslips were washed 3 times for 5 min using PBS. Cells were then 
incubated with FITC-conjugated goat anti-rabbit secondary antibody prepared in 
PBS and was incubated for 30 min in the dark at room temperature. Cells were 
washed for 3 washes for min. Then, coverslips were mounted with Vectashield 
hardset fluorescent mounting medium containing DAPI as a nuclear 
counterstain and were kept at 4°C until further analysis.  
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2.2.5 Detection of polySia in cells 
In this study, two polySia labelling methods were used to detect polySia 
expression: anti-polySia antibody (mAb 735) and endoN-GFP. 
2.2.5.1 Polysialic acid detection using anti-polySia antibody (mAb 735) 
An indirect immunofluorescent method was used to assess the expression of 
polySia in cells. When cells reached 70% confluence, cells were washed with 
HBSS and trypsinized as described in section 2.2.3.2. Cells were seeded onto 
autoclaved 22x22 mm glass coverslips in a six-well plate in 1 ml medium. The 
plates were incubated overnight at 37°C in a 5% CO2 atmosphere. All 
experimental steps were carried out at room temperature except where stated.  
Once cells had adhered, the coverslips were rinsed twice with HBSS and fixed 
with ice cold methanol at (-20°C, 30 min) or 4% PFA (room temperature, 15 
min). Then, coverslips were air-dried and they were either stored at -20°C until 
use or immediately hydrated with 3 washes of PBS, pH 7.4, for 5 min each. 
Cells were incubated for 10 min with 1.5% normal serum prepared in PBS of the 
species in which the secondary antibody was raised, which here was normal 
rabbit serum. This blocked the non-specific binding of antibodies. Serum was 
removed and cells were labelled with primary mouse anti-polySia monoclonal 
antibody prepared in 1.5% NRS for 30 min. The coverslip was washed three 
times, 5 min each with PBS. TRITC-conjugated polyclonal rabbit anti-mouse 
antibody was added and cells were incubated for 30 min in the dark. Unbound 
secondary antibody was removed by washing cells three times with PBS for 5 
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min. Finally, coverslip was mounted with Vectashield hardset fluorescent 
mounting medium with DAPI onto a microscope slide and slides were stored at 
4°C.   
2.2.5.2 Detection of polySia expression using endoN-GFP 
Polysialic acid can also be detected using a live cell antibody mimic probe, 
endoneuraminidase (Endo-N) tagged with green fluorescent protein (GFP), 
which is a catalytically inactive form of endo-N. The methodology used was 
adapted from (Jokilammi et al., 2004).  
When cells reached 70% confluence, cells were washed with HBSS and 
trypsinized as described in section 2.2.3.2. Cells were seeded onto autoclaved 
22x22 mm glass coverslips in a six-well plate in 1 ml medium. The plates were 
incubated overnight at 37°C in a 5% CO2 atmosphere. All experimental steps 
were carried out at room temperature except where stated. Once cells had 
adhered, the coverslips were rinsed twice with HBSS and fixed with ice cold 
methanol at (-20°C, 30 min) or 4% PFA (room temperature, 15 min). Then, 
coverslips were air-dried and they were either stored at -20°C until use or 
immediately hydrated with 3 washes of PBS, pH 7.4, for 5 min each. The non-
specific binding of cells was blocked by 1.5% Normal Horse Serum (NHS) in 
PBS for 1 h at room temperature. Then, different endoN-GFP concentrations 
were prepared in PBS was added to the cells and incubated in the dark for 1 h. 
Coverslips were then washed three times in PBS for 5 min and were mounted 
with Vectashield hardset fluorescent mounting medium containing DAPI as a 
nuclear counterstain and were kept at 4°C. 
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2.2.6 Detection of the expression of other sialic acids  
As covered in the introduction section, in order to confirm specificity of polySTi, 
it is important to know its effects on other sialic acid expression, i.e. α-2,3 and 
α-2,6 sialic acids. Prior to use the methodology, MAL I, SNA and MAL II 
optimised as follows: 
2.2.6.1 Optimisation of FITC labelled MAL I and SNA 
Cells were grown onto autoclaved 22x22 mm coverslips in their required 
medium (stated in section 2.2.3). Cells were washed with HBSS twice and 
labelled with a range of concentrations of lectins (range: 2, 10, 15, 20 μg/ml) for 
different incubation times (15 or 30 min) and at different temperatures (i.e. room 
temperature or 37°C). After three washes with PBS to remove unbound lectins, 
cells were fixed with either 4% PFA (15 min, RT) or ice cold methanol (30 min, -
20°C). The negative control was treated with diluents instead of MAL I and 
SNA. After fixation, cells were washed three times with 1 ml of PBS and then 
mounted with Vectashield hardset fluorescent mounting medium with DAPI onto 
the microscope slides. The slides were stored at 4°C and evaluated 
microscopically as described in section 2.2.8.  
2.2.6.2 Optimisation of biotinylated labelled MAL II 
Maackia amurensis leukoagglutinin lectin II (MAL II) was optimised by growing 
cells onto autoclaved 22x22 mm coverslips. Cells were washed with HBSS 
twice and fixed with either ice cold methanol or 4% PFA. The negative control 
was treated with diluents instead of biotinylated MAL. Different concentrations 
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(range: 2, 10, 15, 20 μg/ml) of biotinylated lectin were prepared using the 
manufacture‟s guideline and incubated for 1 h at room temperature. This was 
followed by the addition of fluorescent at avidin different concentrations and 
incubated in the dark for 30 min. The slides were stored at 4°C.  
2.2.7 Validation of labelling tools using CMP  
For utilising the tools in the evaluation of polySTi, they need to be validated 
using known inhibitor, CMP. Cells were treated with different concentrations (1 
mM, 3 mM, 5 mM and 7 mM) for 24 h at 37°C in a 5% CO2.  
2.2.8 Imaging 
Fluorescence images were obtained with a Leica DM2000 microscope and 
captured using a Leica digital camera and Leica Application Suite (LAS) 
software (Leica Microsystems CMS GmbH, Wetzlar, Germany). 
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2.3 Results 
2.3.1 Kinetics of cell growth  
Growth curves were established using the MTT assay for the tumour cell line 
panel, to determine the optimum cell seeding densities which would ensure that 
cells would be in the exponential phase of growth when performing the various 
assays used in these studies (Figure 2.2). 
For IMR-32, cell growth was only seen at higher concentration: 5x104 cells/ml 
and 1x105 cells/ml concentrations, whereas other cell lines showed the 
exponential (lag) phase from Day 0.  
From the data, 1x104 cells/ml (DLD-1, C6-STX and C6-WT) and 1x105 cells/ml 
(IMR-32 and SH-SY5Y) were the optimal density selected in this thesis for 
further analysis unless otherwise stated. 
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Cells were plated in 96-well plate on day 0 and absorbance was measured in 
their subsequent days. Results were expressed as absorbance mean ± SD 
(n=3). 
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Figure 2.2: Growth curves using the MTT assay. 
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2.3.2 Characterisation of polySia and NCAM expression in the cell line 
panel using cytochemical and immunocytochemistry techniques  
Confirming the expression of polySia (using both probes mAb 735 and endoN-
GFP) and NCAM in the cell line panel was carried out as previously described 
(Figure 2.3). Variables including concentration, temperature, incubation time 
and fixatives were investigated (Figure 2.3). The concentrations of endoN-GFP 
and mAb 735 were as previously used whereas a higher concentration of 
NCAM was used. 
PolySia expression was evaluated using neuroblastoma cell lines IMR-32 and 
SH-SY5Y and polySia membranous labelling was seen in both cell lines. 
Isogenic C6 rat glioma cells were also studied, one is wild-type (C6-WT) 
expressing NCAM only and the other was transfected with STX (C6-STX) 
expressing both NCAM and polySia. In this, polySia labelling was found only on 
C6-STX cell lines and no labelling was observed in C6-WT cell as expected.  
The polySia expression pattern seen was similar in IMR-32, SH-SY5Y and C6-
STX cells for both mAb 735 and endoN-GFP.  
For NCAM, all cell lines highly expressed this protein apart from DLD-1 which 
was selected as a negative control, expressing no polySia, polySTs or NCAM 
and hence no labelling patterns were seen with endoN-GFP, NCAM or mAb 735 
as shown in Figure 2.4.  
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Figure 2.3: Flow-diagram of polySia labelling tools and NCAM to detect 
expression in the panel. 
Keywords: PFA: paraformaldehyde; NRS: Normal Rabbit Serum; NGS: 
Normal Goat Serum; NHS: Normal Horse Serum; mAb 735: anti-polySia 
antibody; h: Hours; RT: room temperature. 
Optimisation of  mAb 735, endoN-GFP and NCAM  
Blocking non-specific binding with serum  
methanol 4%PFA 
mAb 735: NRS endoN-GFP: NHS NCAM: NGS 
Different fixatives 
mAb 735  and NCAM: secondary antibodies ; Dilutions: 1:25-1:100, 
incubated  30 mins, 1 h, RT, 37 C 
endoN-GFP: different concentrations: 5-20 µg/ml 
mAb 735: 1:50 endoN-GFP: 10 µg/ml NCAM:1:50 
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Figure 2.4: PolySia and NCAM expression of a panel of cell lines. 
IMR-32, SH-SY5Y, C6-STX, C6-WT and DLD-1 cells were labelled with mAb 735, endoN-GFP and NCAM. The negative controls with only 
secondary antibody (mAb 735; NCAM) and serum (endoN-GFP) whereas positive controls had primary antibodies or endoN-GFP. Membranous 
polySia expression was seen in IMR-32, SH-SY5Y and C6-STX cells, whereas no labelling was seen in C6-WT and DLD-1 cells (polySia: red, 
NCAM and endo-GFP: green; counterstained with DAPI: blue). Both mAb 735 and endoN-GFP produce the same polySia labelling pattern. The 
images shown are representative of three independent experiments. Scale bar: 25 µm. 
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2.3.3 Validation of polySia labelling tools using CMP 
Using immunocytochemistry, the specificity of polySia labelling tools was 
validated using a molecule known to inhibit polySia biosynthesis, CMP (Al-
Saraireh et al., 2013). 
Cells were grown on coverslips and treated with increasing concentrations of 
CMP for 24 h and then immunostained (section 2.2.5). Whilst it would be 
expected that increasing the CMP concentration might result in a decrease in 
polySia expression, this was only detected at high concentrations (7 mM) 
(Figure 2.5). Therefore, to confirm these findings, endoN-GFP was used. A 
similar result was obtained. The lack of effect of CMP was also evident in other 
cells, IMR-32 and C6-STX (Figure 2.6).  
From the images, it was difficult to see any effect CMP had on the membranous 
expression of polySia. One possibility could be that it was difficult to distinguish 
between old and new membranous polySia labelling and thus no effect of CMP 
was seen. Therefore, the next step was to use an assay where all pre-existing 
expression of polySia was removed first, before challenging the cells with 
polySTi and assessing for re-expression of polySia.  
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Figure 2.5: Detecting the effect of CMP on SH-SY5Y cells. 
Cells were treated with increasing concentrations of CMP for 24 h and subsequently characterised using monoclonal antibody (mAb 735) 
and fusion protein (endoN-GFP). The positive controls (absence of CMP) contained endoN-GFP and anti-polySia antibody (mAb 735) (mAb 
735: red; endoN-GFP: green: nuclei counterstained with DAPI: blue). The effect was only detected at 7mM. Scale bar: 25 µm. 
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Figure 2.6: CMP has no apparent effect on polySia expression following 
direct treatment on cells.   
Cells were treated with CMP (24 h) and characterised with mAb 735 (A) and 
endoN-GFP (B). The positive controls (no CMP) contained endoN-GFP and 
mAb 735 No obvious inhibitory effect was observed on the polySia when treated 
with 5 mM CMP for 24 h. (mAb 735: red; endoN-GFP: green; nuclei 
counterstained with DAPI: blue). Scale bar: 25 µm. 
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2.3.4 Optimisation of tools for sialic acid detection  
As previously described, it is important to establish the specificity of polySTi for 
polySTs over other members of the wider sialyltransferase family. The 
specificity of polySTi was studied by using differential staining tools (lectins) for 
α-2,3 and α-2,6 sialic acids. Here, lectins MAL I, MAL II and SNA were utilised 
to detect expression of α-2,3 sialic acid and α-2,6 sialic acid respectively.  
In initial experiments, cells were treated with different concentrations of lectins, 
including 2, 5, 10, 20 µg/ml and with different fixatives including 4% PFA or ice 
cold methanol using three different experimental conditions. MAL I and SNA 
was optimised using 20 µg/ml lectin concentration (Figure 2.7 and Figure 2.8).  
MAL II was optimised using different experimental conditions including 
concentration of lectin (including 10-30 µg/ml), followed by fluorescent Avidin 
(Texas Red or fluorescein) with 4% PFA or methanol, and shown in Figure 2.9.  
In the optimum conditions, the expression of α-2,3 sialic acid and α-2,6 sialic 
acid was clearly seen on the cell surface. Then these conditions were applied in 
a panel and found that all cell lines were expressing α-2,3 sialic acid and α-2,6 
sialic acid detected using MALI, MALII and SNA (Figure 2.10). 
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Figure 2.7: Optimisation of fluorescein labelled Maackia Amurensis lectin I 
(MAL I). 
(A) IMR-32 cells were labelled with different concentrations of MAL I using 
different fixatives. (B) Different experimental conditions; 15 min, room 
temperature; 30 min, room temperature; 15 min, 37°C were applied using 4% 
PFA or ice cold methanol using 10 µg/ml of lectin. (C) The optimised protocol 
showed a representative example for IMR-32 cells. Scale bar: 60 µm. 
 
Optimisation of MAL I 
(A) Range of lectin concentrations 
methanol 4%PFA 
2 µg/ml 5 µg/ml 10 µg/ml 20 µg/ml 
(C) Optimised conditions: 
20 µg/ml; 30 mins RT using methanol 
15 min, RT 30 min, RT 15 min, 37 C 
Negative control 
(B) Comparing fixatives at different temperatures and incubation times 
Positive control 
15 min, RT 30 min, RT 15 min, 37 C 
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Figure 2.8: Optimisation of fluorescein labelled Sambucus nigra (SNA). 
(A) IMR-32 cells were labelled with different concentrations of SNA. (B) 
Different experimental conditions; 15 min, room temperature; 30 min, room 
temperature; 15 min, 37°C were applied using 4% PFA or ice cold methanol 
using 10 µg/ml of lectin. (C) The optimised protocol showed a representative 
example for IMR-32 cells. Scale bar: 60 µm. 
 
 
Optimisation of SNA 
(A) Range of lectin concentrations 
methanol 4%PFA 
2 µg/ml 5 µg/ml 10 µg/ml 20 µg/ml 
(C) Optimised conditions: 
20 µg/ml; 30 mins RT using methanol 
15 min, RT 30 min, RT 15 min, 37 C 15 min, RT 30 min, RT 15 min, 37 C 
Negative control 
(B) Comparing fixatives at different temperatures and incubation times 
Positive control 
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Figure 2.9: Optimisation of the Biotinylated labelled Maackia amurensis II 
(MAL II) lectins (α-2,3 sialic acid) in SH-SY5Y cells. 
(A) SH-SY5Y cells were labelled with different concentrations of lectin [(i) 10 
μg/ml and (ii, iii) 20 μg/ml] and avidin [(i, iii) 30 μg/ml and (ii) 15 μg/ml] using 
different fixatives but showed background fluorescent. (B) Comparing 
Fluorescein and Texas Red avidin on SH-SY5Y cells using methanol. The 
concentrations of lectins were (iv, v) 10 μg/ml and (vi) 20 μg/ml and avidin 
concentrations were (i) 5 μg/ml; (ii) 30 μg/ml and (iii) 15 μg/ml and lectin 10 
μg/ml was selected. (C) The optimised protocol applied to SH-SY5Y cells 
showing a representative image of two independent experiments. Scale bar: 
25 µm. 
Optimisation of MAL II 
(A) Range of lectin concentrations using  different fixatives 
methanol 4%PFA 
(C) Optimised conditions 
 (i) (ii) (iiii) (i) (ii) (iii) 
Negative control Positive control 
(B) Comparing Fluorescein and Texas Red avidin 
Texas Red Fluorescein 
 (iv) (v) (vi) (iv) (v) (vi) 
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Figure 2.10: Characterisation of sialic acid expression using lectins.  
Maackia Amurensis (MAL I), Sambucus nigra (SNA) and Biotinylated labelled lectins Maackia amurensis (MAL II) predominantly binds 
sialic acid that in linkages α,2-3 and α,2-6 in a panel respectively. Nuclei were counterstained with DAPI (blue) and each lectin binding is 
visualised in green. Scale bar: 25 µm. 
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2.3.5 Validation of lectin labelling probes with CMP  
The specificity of CMP for polyST was confirmed using endoN-GFP which is an 
antibody-mimic probe to detect polysialylation. Cells were treated for 24 h with 
increasing concentrations of CMP (1 mM, 3 mM and 5 mM) and showed no 
effect on STs (i.e. α-2,3 or α-2,6 sialic acids) (Figure 2.11).  
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Figure 2.11: Effect of CMP on other sialic acids expression. 
SH-SY5Y cells were treated with CMP for 24 h and their sialic acid expression was visualised using direct fluorescein labelled Maackia 
amurensis (MAL I), Sambucus nigra (SNA) and Biotinylated labelled lectins Maackia amurensis (MAL II) followed by avidin Texas red 
detecting α-2,3 sialic acid and α-2,6 sialic acids respectively and found no obvious inhibiting effect (MAL and SNA: green; and nuclei 
counterstained with DAPI: blue). Scale bar: 25 µm. 
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2.4 Discussion 
The main aims of this chapter were to assemble a panel of cell lines and the 
detection tools of sialic acids which can be used to screen novel inhibitors of 
polyST.  
Initially, cell growth was characterised using the MTT assay which monitors cell 
proliferation, in order to optimise cell seeding densities for different growth 
periods for use with the other assays, so that cells to be used would be in an 
exponential growth phase during the experimental duration. It was seen that 
C6-STX and C6-WT cells grew more quickly than the neuroblastoma cell lines, 
and seeding density was adjusted accordingly in other assays. 
Tissue culture technique provides a powerful system for the discovery and 
validation of the new anticancer targets. In this study, naturally and non-
naturally expressing positive and negative cells were selected. Since 
neuroblastoma was the interest of this thesis, two naturally expressing polySia 
cell lines IMR-32 and SH-SY5Y were selected.  
A pair of rat isogenic cell lines were also utilised here. This provided the model 
for screening but these cells do not exist in nature. In this case C6 glioma cells 
were engineered to over-expressed STX, an enzyme responsible for 
polysialylation in neoplastic cells (Cheung et al., 2006). This model allowed us 
to carry out unambiguous studies of polySTi with a defined expression 
difference between WT and STX, without the typical confounding problem seen 
with unrelated cancer cell lines. The rat isogenic cell lines were extensively 
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used showing that C6-STX cells migrate and invade more than C6-WT cells in 
vitro indicating a useful model for screening and validating the effects of polySTi 
(Al-Saraireh et al., 2013, Suzuki et al., 2005). PolySia positive cells (C6-STX) 
invaded more than polySia negative cells (C6-WT) across the corpus callosum 
when injected (Suzuki et al., 2005). Other studies have shown that knock down 
of STX (i.e. endo-N) reduced migration caused by polySia (Eggers et al., 2011). 
Therefore, these studies concluded the implication of STX as an anti-polySia 
target and useful model for screening polySTi.  
Additionally, the naturally null expressing DLD-1 cell was used as a negative for 
polySia, polyST and NCAM expression.  
PolySia is synthesised by two polyST enzymes. During development, STX is 
highly expressed in embryonic brain whereas PST is expressed in the adult 
brain as mentioned in Chapter 1. STX is thought to be responsible for polySia 
re-expression in tumours as shown previously (Cheung et al., 2006, Suzuki et 
al., 2005). Due to a lack of antibodies recognising polyST, antibodies and 
probes are required to detect polySia expression. Previous studies have 
indicated the direct correlation of polySia with the expression of polyST 
enzymes and polySia cell surface expression is dependent on the polyST 
transcriptional level (Hildebrandt et al., 1998). For this, in this chapter different 
tools were utilized to assess the expression of polySia. Two methods can be 
used to assess the effects of polySTi on the polySia expressing cells. EndoN-
GFP is a useful tool for detection of polySia expression in live cells, which binds 
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to polySia directly and rapidly without degrading polySia (Jokilammi et al., 
2004). 
Another is anti-polySia antibody mAb 735, which binds with polySia specifically 
(Frosch et al., 1985). By analysing tumour cell lines, the expression of polySia 
was validated in polySia expressing cells (i.e. IMR-32, SH-SY5Y and C6-STX), 
whereas no expression was detected in polySia negative cells (i.e. C6-WT and 
DLD-1). The cell surface labelling patterns of polySia were the same with both 
mAb 735 and endoN-GFP, making these tools equally specific for cell surface 
expression of polySia (Jokilammi et al., 2004). 
The expression of polySia and NCAM were examined using anti-polySia and 
anti-NCAM antibodies and endoN-GFP. Cells expressing both polyST enzymes 
had high level of polySia expression (i.e. IMR-32), compared with SH-SY5Y 
which only expressed STX (Jimbo et al., 2001, Hildebrandt et al., 1998). This is 
consistent with previous work suggesting that both polySTs form polySia in a 
synergistic way (Angata et al., 1998).  
A pair of isogenic C6 rat glioma cells, engineered to overexpressed STX (C6-
STX) was also utilised here as polySia-positive cells, whereas C6-WT only 
expressed NCAM.  
There was no expression of polySia or polySTs seen in C6-WT and DLD-1 cells 
(Figure 2.4) (Jimbo et al., 2001). The results in this thesis regarding polySia 
and NCAM expression are consistent with PCR and western blot data 
generated previously (Al-Saraireh et al., 2013).  
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In this study, mAb 735 was primarily used since it gave more consistent results 
compared to endoN-GFP, which was light sensitive and easily photo-bleached, 
resulting in low intensity signal. Therefore, for the merit of this, mainly mAb 735 
was used in the functional assays (Chapter 4).  
PolySia labelling tools were used to determine the effect of polySTi (Chapter 4) 
by utilising a known polySTi (CMP) on tumour expressing polySia cells with 
immunocytochemical technique. The effect of CMP was inconclusive or was 
difficult to interpret between old and new polySia chains at a lower 
concentration. But the clear effect was seen at 7 mM CMP. Therefore, a better 
way to determine the effect of CMP is using the recovery assay (see Chapter 
3).  
It is essential to determine the selectivity of polySTi as these inhibitors could 
affect α-2,3-ST and α-2,6-ST. Since sialic acids have extensive roles, this could 
be a source of off-target effects. Therefore, it was important to determine the 
specificity of the compounds for polySTs. CMP as a tool to evaluate the validity 
of the sialic acid lectin labelling approach had no differential effects on α-2,3-
sialic acid and α-2,6-sialic acid.  
Furthermore, this methodology needs further validation using known inhibitors 
of STs. For example, Lithocholic acid (LA), new and potent α-2,3-
sialyltransferase inhibitor (Chang et al., 2006) and its analogue (AL10) has 
shown the inhibition of a-2,3-ST using human lung cancer cells (CL1-0, CL1-5) 
(Chiang et al., 2010).  
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Seeds from the legume tree seeds of Maackia amurensis express two Sia-
specific lectins, hemagglutinin (MAH/MAL II) and leukoagglutinin (MAL/MAL I). 
In this study, MAL I and MAL II were obtained from Vector Laboratories 
assuming MAL I is MAL and MAL II is MAH. This resulted in confusion of using 
two isoforms for detecting α-2,3 sialic acid expressions in a panel of tumour 
cells. MAL has a greater affinity to bind with the sequences of trisaccharides 
include α-NeuAc(2,3)βGal(1-4)βGlcNAc/Glc in contrast to MAL II which has a 
greater affinity for tetrasaccharides (αNeuAc(2,3)βGal(1,3)[α-NeuAc(2-
6)]αGlaNAc) (Imberty et al., 2000, Knibbs et al., 1991, Konami et al., 1994, 
Wang and Cummings, 1988) but MAL II has been used specifically for the 
detection of α-2,3 sialic acid.  
The specificity of these lectins can vary with different experimental parameters 
and cell lines. This is the case with SNA, where specificity for α-2,6 sialic acid 
has been shown in different studies (Shibuya et al., 1987). For instance, one 
study mentioned SNA recognising 6-O-sulfation of galactose (β1-4 to GlcNAc 
linkage) using affinity chromatography (Shibuya et al., 1987, Yamashita et al., 
1992).  
In the present thesis, it has been concluded that these lectins are useful to 
distinguish between α-2,3 sialic acid and α-2,6 sialic acid from polySia. 
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2.5 Conclusion 
In conclusion, in this chapter a panel of cell lines and appropriate detection tools 
has been assembled for use in further studies. The panel consists of cell lines 
that naturally express polySia (IMR-32 and SH-SY5Y), a null expressing natural 
cells (DLD-1), plus an isogenic pair of cell lines with high or low expression (C6-
STX and C6-WT), and expression of polySia was confirmed using 
immunocytochemical and cytochemical techniques. In addition, expression of α-
2,3 sialic acid and α-2,6 sialic acid was characterised using lectin differential 
probes.  
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3 Development and validation of functional assays for use in 
the screening of novel polyST inhibitors  
3.1 Introduction 
As presented in Chapter 1, there is strong evidence for the role of polySia in 
promoting tumour dissemination. This has led to the therapeutic strategy of 
reducing polySia expression by inhibiting its synthesis using polySTi, which is 
the focus of this thesis. 
In Chapter 2, a panel of tumour cell lines was characterised in terms of polySia 
and polyST expression. The next step is the assembly of a battery of functional 
assays for the evaluation of polySTi. The first assay, the polySia recovery assay 
will be employed here to evaluate the effects of potential polySTi. This assay 
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monitors cell surface re-expression of polySia, and was adapted at the ICT from 
(Kiss et al., 1994), as described (Al-Saraireh et al., 2013). Briefly, endo-N is 
used to remove pre-existing polySia from the cell surface, and re-expression of 
polySia in the presence of inhibitor is monitored using immunocytochemistry. 
This strategy will be further explored in Chapter 4.  
The next step is to monitor if the polyST inhibitor has an effect on cancer cell 
function in relation to tumour dissemination. Therefore, an appropriate assay is 
required to study the processes (i.e. adhesion, migration and invasion) involved 
in tumour dissemination. Assays which evaluate migration are already 
established for use in the screening of novel polySTi in-house, therefore the 
focus here is to investigate another facet of tumour dissemination; invasion. 
Invasion and metastasis are the primary characteristics of cancer-related 
metastatic disease, and account for 90% of cancer-related deaths (Hanahan 
and Weinberg, 2000). Invasion can be defined as the movement of cells 
through the extracellular matrix (ECM).  
There are various in vitro invasion assays (Table 3.1) available for studying 
tumour cell invasion, including transwell invasion assays, 3D cell tracking and 
spheroid invasion assays. These assays are widely used as they are 
inexpensive, easy to handle, highly reproducible and suitable for high 
throughput drug screening. These techniques could be employed to study a 
single step of the metastatic process and the most important step is the 
invasion of the basement membrane (Albini et al., 2004). 
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In this study, transwell invasion assay (also known as Boyden chamber assay 
(Boyden, 1962)) has been utilised to investigate the effect of polySTi on tumour 
cell invasion. In this assay, two compartments are separated by a porous 
membrane filter, coated with a thin layer of ECM prior to cells being seeded into 
upper wells permitting cell invasion to the lower chamber in response to the 
presence of chemoattractants in the chamber (e.g. low to high serum gradient) 
(Albini et al., 2004, Marshall, 2011). ECM coating the membrane prevents non-
invasive cells from migrating through the membrane. The number of invaded 
cells observed in response to chemoattractant can be counted by a light 
microscope. Transwells are commercially available with different pore sizes (3 
µm-12 µm) or alternatively, different ECM coatings can be used with different 
cell types.  
In this study, Matrigel coating was used, which is prepared from murine 
Engelbreth-Holm-Swarm (EHS) tumour, which contains laminin, collagen IV, 
entactin and other growth factors (Benton et al., 2014). Matrigel is a good model 
for ECM and coating transwells with Matrigel allowed a rapid quantification of 
the invasive potential of metastatic cells (Albini et al., 1987). Invasion assays 
have previously been employed using SH-SY5Y neuroblastoma cells treated 
with the synthetic Sia precursor (ManNProp; see chapter 4 for details), resulting 
in a reduction in the invasion ability of these cells (Gnanapragassam et al., 
2014). Therefore, this assay has been applied here to evaluate the effect of 
novel polySTi on polySia mediated invasion (Chapter 4). 
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Despite the advantages described, one limitation of the transwell invasion assay 
is that it does not fully recapitulate in vivo cellular invasion, which is complicated 
by factors such as tumour heterogeneity and 3D invasion patterns. Therefore in 
order to confirm that the relevance of the results seen with the transwell 
invasion assay, a 3D spheroid invasion assay, which better represents the in 
vivo situation was thus employed here. In this method, spheroids of invasive 
cells (e.g. U87MG, C6) are embedded in different ECMs (such as collagen I, 
matrigel), with invasion being measured and compared to non-invasive cells 
after cultivation (Nowicki et al., 2008). Invasion of cells can be analysed by live 
imaging and quantified using imaging software (i.e. Image J). Furthermore, the 
spheroids can be immunostained and processed using confocal microscopy 
(Wolf et al., 2007). The key advantage of this assay is the movement of cells in 
a 3D matrix, which closely mimics invasion in vivo. This is significant as 
invasion in spheroids occurs from spheroids (cell clusters) with well-established 
cell-cell interactions instead of single cells, since this situation is found in cancer 
cells (Kramer et al., 2013). But there are also other advantages which are listed 
in Table 3.1. 
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Keywords: AD: any dependent; ND: not determined; 3D: three dimensional; +: suitable; -: Not suitable; ICC: immunocytochemistry; IHC: 
Immunohistochemistry; BME: Basement membrane extract; HTC: high throughput screening; NA: not applicable.     
 Transwell 
invasion 
assay 
Platypus 
invasion 
assay 
3D cell 
tracking 
Gelatin 
degradation 
assay 
Vertical gel 
invasion 
Spheroid/monodispersed 
cell invasion assay 
Spheroid 
conformation 
assay 
Spheroid 
invasion 
assay 
Chemotaxis + - AD - - ND ND - 
Measurement Cell 
number 
Invasion 
area 
Invasion 
distance 
Matrix 
degradation 
area 
Deepness 
of invasion 
Cell number NA Invasion 
area 
Live imaging - + + + - - - + 
ICC/IHC - + AD + + + + + 
Substrate BME, 
Collagen I 
BME ECM Gelatin ECM ND ND ECM 
Direction of 
movement 
Vertical Horizont
al 
Any Vertical Vertical Any Any Any 
HTS + + + - - - - - 
Analysis Endpoint Kinetics Kinetics Kinetics/ 
Endpoint 
Endpoint Endpoint Endpoint Kinetics 
Table 3.1: Comparing commonly used methods to evaluate tumour cell invasion. Taken from (Kramer et al., 2013). 
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3.1.1 Aims and objectives 
The main aims of this chapter are to develop and validate functional assays for 
the analysis of novel inhibitors of polyST. These aims will be addressed by the 
following objectives: 
 Validation of the polySia recovery assay to evaluate the inhibition of 
polySia using the characterised inhibitor CMP. 
 Development and validation of a 2D Matrigel functional invasion assay to 
evaluate polySTi, again using the characterised inhibitor CMP. 
Confirmation of the relevance of the results seen with the 2D Matrigel 
assay using a 3D spheroid assay. 
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3.2 Materials and Methods 
3.2.1 Materials 
All cell culture reagents and general chemicals used are as specified in Chapter 
2 unless otherwise stated. Details of the cell lines investigated in this study are 
given in section 2.2.2. Endoneuraminidase N (endo-N) (0.3 µg/ml) was 
purchased from AbCyss (Paris, France) and stored at -20°C. 
3.2.2 Polysialic acid recovery assay 
When cells reached 70% confluence, they were washed with HBSS and 
trypsinized as described above. Cells were seeded onto autoclaved 22x22 mm 
glass coverslips in 6-well plates. The plates were incubated overnight at 37°C in 
a 5% CO2 atmosphere. All experimental steps were carried out at room 
temperature except where stated.  
Once cells had adhered, coverslips were rinsed twice with HBSS and treated 
with endo-N in cell culture medium for 24 h to remove the pre-existing polySia 
on the cell surfaces. Cells were fixed directly after endo-N digestion to confirm 
polySia removal (control). Cultures with endo-N treatments were incubated with 
either with medium or CMP for 6 h (Figure 3.1).  
Recovery of polySia was confirmed by incubating cultures with the complete 
medium only (6 h). All these groups were fixed with ice cold methanol at -20°C 
for 30 min. Then coverslips either stored at -20°C or immunocytochemistry was 
performed immediately as stated in section 2.2.5.  
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The slides were stored at 4°C and images captured using a Leica DM2000 
optical microscope. Semi-quantified analysis was carried out by counting 
polySia positive cells compared with total number of cells using DAPI. Results 
were expressed as percentage of polySia expression relative to the untreated 
control and as the mean ± SD of three independent experiments. 
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Figure 3.1: Schematic representation of polySia recovery assay. 
 
Cells on coverslips 
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3.2.3 In vitro invasion assays 
In order to evaluate one of the potential effects of polySTi on tumour 
dissemination, two assays (the transwell and the spheroid invasion assay) were 
utilised to look into invasion. 
3.2.3.1 Matrigel invasion assay 
The transwell invasion assay was adapted from (Albini et al., 1987). Transwell 
chambers containing 8 μm pore-size polycarbonate inserts (Corning, USA) were 
coated with different concentrations of Matrigel prepared in ice cold buffer [0.01 
M Tris (pH 8.0), 0.7% (w/v) NaCl] (Beckon Dickinson, UK) and incubated for 2 h 
at 37°C and allowed to dry.  
Cells were incubated in either in 10% FBS as a chemoattractant or serum free 
medium. Cells were detached with trypsin or solution Accutase (Sigma-Aldrich, 
UK). Cell suspension (150 μl) was added to upper compartments and 600 μl of 
medium with chemoattractant added to the lower chamber (Figure 3.2).  
The inserts were incubated for 24 h at 37°C in a humidified atmosphere 
containing 5% CO2 allowing cells to invade the Matrigel (source of ECM).  
Non-invading cells on the upper surface of the membranes were carefully 
removed using cotton buds, whereas the invading cells on the lower membrane 
fixed with 70% (v/v) ethanol and stained with Vectashield hardset fluorescent 
CHAPTER THREE 
 
 
92 
 
mounting medium with DAPI onto microscopic slides and visualised under the 
microscope, followed by further analysis.  
For quantification, images of ten random fields (20X objective lens) for each 
filter were taken and nuclei stained with DAPI were counted. The average of 
three independent experiments were taken and normalised against the total 
number of cells in the positive control. 
Once the invasion parameters of the assay were optimised, the assay was used 
to evaluate the invasive properties of the cells in the presence of known 
polySia-interfering molecules CMP (5 mM) and endo-N (0.3 µg/ml) for 24 h. 
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Figure 3.2: Schematic presentation of the Matrigel invasion assay.  
Cells are suspended in serum free medium and added in the upper chamber. 
Transwell is consisting of 24 well cell culture insert with 8 µm pore size, 
uniformly coated with the Matrigel. Transwell were incubated for 24 h, non-
invading cells removed and invaded cells were counted. 
Incubated at 37 C
Cell suspension was added
Membrane was stained
with haematoxylin
Wipe the inner side of
transwell respectively
Imaged and count cells
Transwell insert was
coated with matrigel
Incubated at 37 C
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3.2.3.2 Spheroid invasion assay 
3.2.3.2.1 Sourcing spheroids and test of viability using the MTT assay  
A schematic representation of the spheroid invasion assay is shown in Figure 
3.3. In this thesis, the hanging drop method is used to prepare spheroids as 
described previously (Del Duca et al., 2004). Different cell concentrations (i.e. 
200, 1000, 10000 cells/30 µl) were prepared and drops (30 µl) placed on the 
inner side of the lids of a petri dish (100 mm dishes). The lid was inverted and 
hanging drop cultures incubated in an incubator at 37ºC. PBS was added at the 
bottom of the petri dish to prevent drops to evaporate since small volume was 
used. Cells were collected at the bottom of the drop, where they proliferate and 
aggregate to form spheroids.  
Spheroids formed from different seeding densities were transferred to the wells 
of a 96 microplates and the detection of viable cells was carried out as for the 
MTT assay on Days 3, 5 and 7 post-seeding (section 2.2.3.3). 
3.2.3.2.2 Collagen invasion Assay 
In order to create a substrate for the invasion assay, type I collagen (Sigma-
Aldrich) (1400 µl) is diluted with complete medium (200 µl) as described 
(Nowicki et al., 2008). The solution is initially acidic; therefore, 1M NaOH was 
added to neutralise the pH to 7.4 so that the collagen gels. 200 µl diluent was 
added into 8-chamber slides and slides were incubated for 30 min at 37°C 
incubator (no CO2) for gelling. Spheroids were then implanted into the gel using 
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Gilson pipette. After gelling at 37°C, the gel was loaded with 200 µl medium and 
incubated for over a week at 37°C, 5% CO2. Prior to imaging, spheroids were 
stained for 24 h by adding Hoechst 33342 stain as counterstain for all nuclei 
when treated with CMP. Images were taken using Lumascope 500 microscope 
and the inverted light microscopy (Nikon Eclipse TE2000-4). 
Spheroid images were analysed using Image J software developed by the 
National Institutes of Health. In brief, the image was initially converted to an 8-
bit type image and then into a binary image (black and white). The analysis 
dialogue was used to calculate the percentage of area covered by spheroid 
structure. In Excel, the percentage of invading cells can subsequently be 
determined from the processed images and compared with the untreated 
control. 
3.2.4 Statistical analysis 
All values are presented as mean ± SD, with each experiment repeated three 
times. Statistical difference between experimental groups was determined using 
Student‟s paired or unpaired t-test where appropriate. Differences were 
regarded as statistically significant when p<0.05 (Joshi et al., 2005). 
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Figure 3.3: Schematic representation of spheroid invasion assay. 
The basic principle involves spheroid formation using hanging drops. 30 µl of cell suspension was added on the lid of a petri  dish; lid 
was inverted and incubated at 37ºC. Spheroids were formed at the base of hanging drops. Spheroid was transferred into 8-chamber 
containing matrix (i.e. collagen) and incubated for 72 h. Images were taken and analyse by Image J software. 
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3.3 Results 
3.3.1 Validation of polysialic acid recovery assay using CMP 
In this assay, endo-N was used to remove pre-existing polySia cell surface 
expression and re-expression was monitored in the presence of polySTi CMP, 
with polySia detected using anti-polySia antibody (mAb 735).  
PolySia-expressing cell lines (IMR-32, C6-STX and SH-SY5Y) were utilised. 
PolySia expression was removed using endo-N (24 h) with expression being 
recovered after 6 h. This was confirmed in the untreated cells (Figure 3.4).  
CMP treatment showed a reduction in the rate of re-expression of polySia in 
SH-SY5Y cells. A concentration of 5 mM was selected due to persistent 
inhibition of polySia being observed and no cell cytotoxicity was seen. Other 
polySia expressing cells IMR-32 and C6-STX showed similar results. A lack of 
polySia expression was confirmed for the negative control, C6-WT. This result 
confirmed that CMP reduces polySia biosynthesis, and that the assay can be 
further utilised to evaluate novel polySTi.  
CHAPTER THREE 
 
 
98 
 
 
 
 
 
 
 
(A) 
Negative Control Positive control Endo-N Recovery 
C
6
-S
T
X
S
H
-S
Y
5
Y
IM
R
-3
2
C
6
-W
T
D
L
D
-1
5mM CMP
CHAPTER THREE 
 
 
99 
 
 
  
Figure 3.4: Recovery of polySia cell surface expression using anti-polySia 
antibody (mAb 735). 
Cells were immunolabelled using anti-polySia antibody (mAb 735) followed by 
exposure to TRITC-conjugated secondary antibody (A). Negative control with 
no anti-polySia antibody, whereas positive control showed polySia expression 
(no CMP or endo-N). Cells were treated with endo-N for 24 h to remove pre-
existing polySia expression, and allowed to recover in culture medium or 
treated with CMP for 6 h (polySia: red; nuclei counterstained with DAPI: blue). 
CMP evidently prevents polySia recovery on the cell surfaces of SH-SY5Y and 
C6-STX cells. The values shown are mean ± SD of 3 independent experiments 
(*, **p<0.05 to positive control) (B). Scale bar: 25 µm. 
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3.3.2 Validation of a Matrigel invasion assay using CMP 
Studies have previously provided evidence of a role for polySia in invasion 
(Suzuki et al., 2005). Therefore, after polyST inhibition using CMP was 
confirmed to reduce polySia cell surface expression, the next step was to 
investigate whether polyST inhibition (and reduction in polySia synthesis) 
inhibits invasion. This was investigated using CMP and the Matrigel invasion 
assay. 
Initially, the Matrigel invasion assay was optimised using different 
concentrations of Matrigel, cell lines, seeding densities and cell suspensions 
prepared in different concentrations of FBS is summarised in (Figure 3.5A).  
Cell invasion was also compared using starved and non-starved conditions and 
also using different cell detachments. It was found that starved cells invaded 
less in solutions containing no chemoattractant (i.e. no FBS) compared to non-
starved cells. Cell starving increased the sensitivity of the cells to the 
chemoattractant and this resulted in reducing spontaneous invasion.  
Correspondingly, more invasion events were observed using Accutase 
compared to trypsin in the positive control. Accutase was selected for cell 
detachment since trypsin can be damaging to cells or receptors, which in turn 
could affect cell invasion.  
Furthermore, C6-STX cells were starved for 4 h in serum-free medium and cell 
suspension were additionally prepared in serum-free medium and detached 
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using Accutase. This resulted in a large number of cells invading in 10% FBS 
(positive chemoattractant) compared with 1% FBS and HBSS (negative 
chemoattractants) (Figure 3.5B). 
CMP and endo-N treatment significantly reduced the invasion of IMR-32, SH-
SY5Y and C6-STX cells compared to the untreated positive control (10% FBS); 
no effect of endo-N or CMP was observed for C6-WT invasion (Figure 3.5C). 
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Figure 3.5: Optimisation and validation of the Matrigel invasion assay. 
(A) Flow diagram of the invasion assay optimisation. The optimisation begins by investigating the effect of different concentrations of 
serum, Matrigel and cell densities. (B) Represented view of cell invasion. The cell suspension was added onto Matrigel-coated 
transwells inserts; invaded cells were stained with DAPI and counted using fluorescence microscopy. (C) The percentage of cells 
invading the insert was calculated as percentage of invasions. The quantitative evaluation of invasion assay showed a higher rate of cell 
invasion in 10% FBS. The data presented as mean ± SD of three independent experiments. The significant reduction in invasion was 
found compared to the positive control (10% FBS) for the endo-N and CMP in polySia expressing cells (IMR-32, SH-SY5Y and C6-STX). 
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3.3.3 Establishment and validation of the spheroid invasion assay using 
CMP 
3.3.3.1 Formation of spheroids using the ‘hanging drop’ method  
To establish the 3D invasion assay for this study, we required the following 
desirable features: (i) single spheroid formation (ii) high reproducibility (iii) ability 
to image and (iv) simple analysis. The hanging drop assay (Del Duca et al., 
2004) has all these features and was applied to form spheroids. 
3.3.3.2 Evaluation of effect of CMP on invasion of C6-STX spheroids 
using a spheroid invasion assay 
C6-STX cells formed compact spheroids. The aggregate become visible after 
24 h to 48 h as shown in Figure 3.6. 
Different cell densities in the hanging drops (100, 1000, 10000 cells/drops) were 
used and an increase in the pattern was found with the increase in 
concentration and time. Even after using different seeding densities, spheroids 
had similar growth trends as measured by the MTT assay (Figure 3.6). 
Furthermore, the doubling time of spheroids is more than the monolayer cells 
(Figure 3.6), signifying that the growth properties of spheroids are a better 
representation of in vivo tumour growth properties. 
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Spheroids are formed and images were taken (showing Day 3, 5, 7 spheroids). 
The MTT assay was carried out on the spheroids on days 3, 5 and 7. The data 
are represented as mean ± SD of three independent experiments. Scale bar is 
20 µm. 
 
Figure 3.6: C6-STX spheroid. 
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The spheroids formed by hanging drops were then transferred into collagen as 
shown in Figure 3.7. Invading spheroid images were then taken and found C6-
STX cells invaded in the collagen.  
The spheroid invasion assay was validated with the known polySTi, CMP. 
Spheroids treated with CMP (1, 3 and 5 mM) showed a slight reduction in 
invasion at Day 3 compared to control (untreated).  
For a better visualisation of the effects, spheroids treated with CMP were also 
stained with Hoechst dye and similar results were observed to those described 
above.  
Comparing 2D and 3D invasion results, it was seen that CMP had a similar 
effect on reducing C6-STX invasion (Table 3.2). Therefore, the 3D invasion 
assay findings validate the 2D invasion assay to be further utilized in Chapter 4. 
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Figure 3.7: C6-STX spheroid invasion in collagen. 
3D invasion assay of C6-STX (A) in a 3D collagen matrix. Spheroid 
invasive distance (white dotted lines) was depicted on the spheroid. (B) 
Viewing spheroid invasion with Hoechst 33342 stain. (C) Quantitative 
analysis of invasion after Day 1, Day 2 and Day 3 treated with CMP. 
White dotted lines indicates cell invasion pattern. Scale bar is 40 µm. The 
data are represented as mean ± SD of three independent experiments. 
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Table 3.2: Validating 2D invasion assay result with 3D invasion assay. 
Parameters 2D invasion assay 3D invasion assay 
Seeding Cells added into transwell Cells grow into spheroids and 
embedded into collagen  
Treatment CMP CMP 
Quantification 
 
Invading through pores were 
calculated 
Invading area was calculated 
Results 
 
 
Conclusion Both assay showed similar effect of CMP reducing C6 invasion. 
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3.4 Discussion 
The main aims of this chapter were to develop and validate assays (i.e. the 
recovery assay and 2D invasion assay) that can be employed in screening the 
novel inhibitors of polyST.  
In Chapter 2, CMP was used as a known polySTi but no consistent effect was 
detected using the direct fluorescence method. Since, it was difficult to 
distinguish between the new and old growth of polySia using the direct method. 
Therefore, to overcome this problem, an alternative in vitro experimental 
approach was adopted to screen for modulation of polySia expression.  
In this assay, recovery of polySia expression was monitored after removing pre-
existing polySia expression from the cell surface using endo-N before 
compound treatment (Kiss et al., 1994). Here, the observed re-expression of 
polySia on the cell surface is due to novel biosynthesis, and comparing the 
levels where polySTi has been administered to untreated cultures, will give an 
indication of the efficacy of the polySTi. Cells treated with CMP showed a clear 
reduction in polySia recovery expression whereas in untreated cells, an almost 
comparable level of polySia was reached in polySia positive cells. Confirmation 
that this decrease in expression is due to STX inhibition was provided by the 
use of isogenic cell lines, compared with no inhibition observed with the C6-WT, 
which does not express this enzyme.  
To-date, cancer therapies have proved unable to reduce tumour dissemination 
in clinical trials (Friedl and Wolf, 2003). Therefore, further understanding and 
targeting the molecular mechanisms involved in tumour dissemination, 
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especially migration and invasion could potentially lead to the development of 
new treatment strategies. The role of polySia in tumour dissemination of various 
tumours has been reviewed in Chapter 1. It is therefore very fascinating to 
target this polySia re-expression, as in-house data showed that CMP caused a 
delay in polySia expressing cell migration in a concentration-dependent manner 
(Al-Saraireh et al., 2013). Therefore, the next step would be to study the effect 
of polyST inhibitors on another feature of tumour dissemination, i.e. invasion, 
since many studies have correlated polySia expression with invasion 
(Scheidegger et al., 1994, Suzuki et al., 2005).  
In this study, the Matrigel invasion assay was selected. Invasion of tumour cells 
requires movement through the basement membrane. Since Matrigel is a 
reconstituted basement membrane, this assay has the advantage over other 
invasion assays in mimicking closely the physiological barrier that cancer cells 
have to invade in order to disseminate (Albini et al., 2004). This assay allowed a 
rapid quantification of cell invasion (Albini et al., 2004). Through extensive 
optimisation of the invasion assay parameters, namely Matrigel concentrations, 
cell lines, cell seeded densities and FBS concentrations; the Matrigel assay was 
developed and validated using CMP and endo-N. 
Several technical issues were encountered in attempting to establish the assay. 
These included a lack of differential between negative and positive controls. 
This was overcome by altering protocol to include serum starvation. This 
prevented spontaneous invasion caused by invading cells towards 
chemoattractant and prepared cells for optimal response to the chemotactic 
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agents. This is consistent with previous studies showing the serum dependency 
of cancer cell invasion (Reshkin et al., 2000).  
Initially, trypsin was used for cell detachment but using Accutase, an enzyme 
containing the mixture of proteolytic, collagenolytic and DNAse activities has 
improved the efficiency of invasion. Trypsin is a protease which could have 
damaged cells or receptors results in either inhibiting or reducing the migration 
ability of cells. In addition, under-trypsinisation caused cells to clump together 
whereas over-trypsinisation cleaves adhesion molecules (including integrins) 
which are essential for migration and invasion (Eccles et al., 2005). With 
Accutase there is a gentle cell detachment, which mimics trypsin and 
collagenase action together and does not require cell neutralisation. In this 
study, the Matrigel invasion assay was optimised using C6-STX cells, as 
previous studies indicated they were more invasive due to polySia compared to 
C6-WT (Suzuki et al., 2005). SH-SY5Y, C6-STX and C6-WT cells were selected 
for further screening. Cells (i.e. IMR-32) invaded in clumps into the transwell 
were difficult to analyse and hence were not selected. 
Here, polySia expression was modulated in two different ways: first with CMP, 
which is a polyST competitive inhibitor reducing polySia synthesis and thereby 
inhibiting invasion. The other is endo-N, which enzymatically cleaves polySia 
specifically, which leads to reduction in invasion. A significant reduction in the 
percentage of invading cells was observed when treated with CMP or endo-N, 
demonstrating the role of polySia in the invasion of polySia-expressing tumour 
cells. To our knowledge, this is the first study demonstrating that reduction in 
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cell-surface polySia through polyST inhibition leads to modulation of tumour cell 
invasion.  
A spheroid invasion assay was also employed here to validate the results of the 
matrigel invasion assay. Having a 3D structure, this assay better mimics the 3D 
cell interactions seen between tumour cells clinically than models based on 
using 2D monolayers (Del Duca et al., 2004). There are many methods 
available to produce spheroids. Each technique has its own strengths and 
weaknesses in terms of spheroids size, shape and structure. Spheroids can be 
formed by coating round bottom plates with agarose (Friedrich et al., 2009), 
poly-HEMA (Ivascu and Kubbies, 2006) and by using the hanging drop method 
(Del Duca et al., 2004). Spheroids produced by hanging-drops were employed 
here.  
The optical cell density and sedimentation times required for hanging drop 
cultures of all cell lines used was determined as a part of this study. It was also 
found that for the hanging drop cultures, the important parameter is cell 
concentration; this affects cells following their ability to form aggregates. This 
method proved to be a reproducible approach for the implantation of spheroids. 
In addition to the control of cell density and spheroid size, this method is more 
effective to study the invasive properties of tumour cells. Different cell densities 
were used to form spheroids of different cell lines so that spheroids have the 
size range of 300 to 500 μm in diameter, which were considered suitable 
starting points for performing the experimental studies (Vinci et al., 2012). 
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Spheroids produced from the hanging drop method were visible after 24 h and 
when embedded in collagen and showed invasion in a typical sun-burst pattern. 
Previous studies have shown that cells with a lower metastatic potential grow in 
tight clumps and cells with highly metastatic produce a star-like appearance, 
allowing a comparison of the morphology of the tumour cells and their malignant 
and invasive properties. For example, breast cancer cell lines such as MCF-7 
forms clumps whereas MDA-MB-231 cells invade in 3D Matrigel culture to give 
a similar star like appearance (Kenny et al., 2007, Benton et al., 2014).  
It is well understood that imaging spheroids with an optical microscope was 
difficult due to high levels of scattering of light on spheroids. The scattering of 
light on spheroids gave bright images, which were difficult to analyse using the 
Image J software. The addition of the spheroids into the 8-chamber wells was 
also problematic; either loss or clusters occurred, causing difficulty in analysing 
the pattern of invasion. Other challenges associated with the use of spheroids 
additionally included maintaining the uniform shape of spheroids, spheroid 
formation using small cell number and qualitative and quantitative analysis of 
spheroids with drugs resting (Mehta et al., 2012).  
The hanging drop method was employed here to form spheroids, which is 
generally a quick and simple approach. But limitations include extensive labour 
and to maintain spheroids was time consuming (Mehta et al., 2012). 
Alternatively, spinner flasks could be applied, in which spheroids form via 
continuous spinning of cell suspensions. This technique is suitable for long term 
culturing but special equipment is required and non-uniform spheroids are 
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produced (Mehta et al., 2012). The uniform and reproducible size of spheroids 
is critical to study the cell behaviour and drug efficacy (Mehta et al., 2012).  
Spheroids are embedded into ECM hydrogels including collagen, acting as a 
physiological model to study metastases (Del Duca et al., 2004, Nowicki et al., 
2008). NCAM and other ECM proteins are known to be highly expressed in 
spheroids of neuroblastoma and glioma cells indicating its importance in both 
cell-cell and cell-matrix interactions (Jung et al., 2013). NCAM belongs to the 
immunoglobulin family, as described in Chapter 1 and would play a role in rein-
forcement of spheroid structures by increasing cell-cell organisation. ECM 
molecules (i.e. collagen I and IV, laminin and fibronectin) will initiate the 
formation of spheroids from C6 cell clusters and this is consistent with another 
study carried out on glioma BT4C spheroids, which enhanced the biosynthesis 
of the ECM (Jung et al., 2013, Bjerkvig et al., 1989).  
Both 2D and 3D invasion assays allowed measurement of the invasion of the 
cells and validation was provided using CMP (Table 3.2). In both assays, CMP 
had significant effects on inhibiting invasion in the C6-STX cells. Therefore, the 
3D-assay confirmed and validated the results of 2D invasion assay, giving 
confidence to progress with the 2D assay in further work to evaluate novel 
potential polySTi in Chapter 4. 
 
 
 
CHAPTER THREE 
 
 
115 
 
3.5 Conclusion 
In this chapter, in vitro assays were established and validated to study the 
effects of polyST inhibition on polySia cell surface re-expression and tumour cell 
invasion (2D and 3D). Thus, these assays could subsequently be used to 
evaluate novel polySTi in the next chapter. 
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4 In vitro pharmacological evaluation of novel small molecule 
inhibitors of polyST   
4.1 Introduction 
In the previous chapters, the assembly of a panel of cell lines with a range of 
polySia expression levels, and the development and validation of the polySia 
recovery assay along with assays to assess invasion have been described. 
Together, these provide the tools to screen novel polySTi. 
Elevated expression of polyST enzymes, particularly STX (Cheung et al., 2006), 
has been reported in certain pathological process including tumour invasion. 
Thus, inhibition of polySTs is potentially useful as an anti-tumour strategy. One 
approach to polyST inhibition is the so-called „biochemical engineering‟ 
approach, whereby unnatural Sia analogues are introduced into the Sia 
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biosynthetic pathway (see review (Keppler et al., 2001)). The enzymes in the 
Sia biosynthetic pathway (Figure 4.1) are permissive to these modifications: N-
acetyl D-mannosamine (ManNAc) is the physiological precursor of N-
acetylneuraminic acid, but N-acyl-modified mannosamines are efficiently 
converted into N-acyl-modified Sia in in vitro and in vivo conditions. This results 
in unnatural sialosides expressed on the surface of the glycocalyx (Mahal et al., 
2001, Bork et al., 2007, Keppler et al., 2001, Kayser et al., 1992), where 
depending on the cell type, this replaces 10-85% of natural physiological Sia 
(for details, see review (Keppler et al., 2001). This „engineering‟ also provides a 
new tool to explore the diagnostic and therapeutic applications of N-acyl side 
chains of Sia listed in Table 4.1. 
Previous studies have shown the application of novel synthetic N-acyl-modified 
D-mannosamines, such as ManNProp, which interferes with NCAM 
polysialylation by changes driven by the polyST enzymes (Mahal et al., 2001, 
Horstkorte et al., 2004a). Conversely, other studies have shown that 
mammalian cells readily utilised ManNProp and N-butanoyl mannosamine 
(ManNBut), but they act as effective inhibitors of polySia synthesis, through 
inhibition of polyST (Mahal et al., 2001, Liu et al., 2000). In this thesis, this 
approach has been used to study the effect of novel small molecules designed 
as polySTi in the ICT on polySia tumour expression and invasion.  
 
 
 
CHAPTER FOUR 
 
 
118 
 
   
 
 
 
 
 
 
 
 
 
 
Sialic acid synthesis starts in the cytosol. Natural ManNAc can be substituted 
with unnatural mannosamines (e.g. ManNProp), which has no effect on other 
enzymatic reactions. These synthetic precursors are processed by the Sia 
pathway in the cytosol and are incorporated into cell surface glycoconjugates. In 
the nucleus, the end product is formed (CMP-Neu5Ac (Sia) /CMP-Neu5Prop), 
which transferred to the Golgi apparatus where sialyltransferases are present. 
Taken from (Seifert et al., 2012). 
Figure 4.1: Representation of the unnatural sialic acids pathway. 
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Keywords: ManNProp: N-propanoyl; ManNBut: N-Butanoyl; ManNPent: N-pentanoyl; ManNGc: N-glycolyl; ManNLev: N-levulinoyl; ManNPent (N- 
pentanoyl) mannosamine. 
Precursor Cell type Biological effect Reference 
                Viral uptake inhibition 
ManNProp 
ManNBut 
ManNPent 
Human B-lymphoma (BJA-B) Loss of virus binding (4 to 8 fold) and reduction (10 to 20 fold) of 
Lymphotropic papovavirus 
 
(Keppler et al., 1995) 
             Neural cells stimulation 
ManNGcPa Rodent neuroblastoma/glioma 
(NG108-15) 
Human T-lymphoma (Jurkat)  
 
Myelin-associated glycoprotein binding to NeuGc positive cells 
abolish 
(Collins et al., 2000) 
                              Introduction of biochemical reactive group 
ManNLev Human T-lymphoma (Jurkat) 
Neutrophil derived (HL-60) 
Cervical epithelial carcinoma 
(HeLa) 
 
Ketone group expression on cell surface used for the selective 
chemical addition of ligands 
(Mahal et al., 1997) 
                                      Altering tumour cells sialylation 
ManNProp Rat leukemic (RBL-3H3) Altering Surface polySia for Immunotargeting tumour cells (Liu et al., 2000) 
ManNProp 
ManNPent 
Human neuroblastoma (SH-
SY5Y)  
Reduced cell surface sialylation, migration and invasion (Gnanapragassam 
et al., 2014) 
ManNProp Human neuroblastoma (IMR-
32)  
Reduced polysialylation and migration (Seifert et al., 2012) 
Table 4.1: Biological implications of the incorporation of unnatural sialic acids.  
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4.1.1 Aims and objectives 
The main aims of this chapter are to evaluate potential novel inhibitors of 
polyST developed in-house at the ICT, in terms of their cytotoxicity, specificity 
and their effect on polySia expression and invasion. 
The aims will be addressed by the following objectives: 
 Assessment of novel polySTi cytotoxicity using the MTT assay (absence 
of cytotoxicity desirable) 
 Confirmation of the specificity of the novel compounds for α-2,8-polySTs 
over other sialyltransferases (α-2,3-ST and α-2,6-ST) using differential 
labelling of sialic acids  
 Investigation of the effects of novel compounds on modulation of cell 
surface polySia expression using the recovery assay characterised in 
Chapter 3 
 Determination of the functional effect of the novel molecules on 
neuroblastoma and glioma cell invasion using a 2D Matrigel invasion 
assay optimised in Chapter 3 
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4.2 Materials and Methods 
4.2.1 Materials 
Unless stated, all reagents, enzymes and antibodies details are as described in 
Chapter 2 and Chapter 3. 
4.2.2 Compounds 
A series of novel polySTi synthesised at the ICT are listed in Table 4.2. Stock 
solutions of each compound were prepared in 100% DMSO at 100 mM and 
stored in aliquots at -20°C.  
For the assays, the compounds were diluted down in culture media so that the 
highest concentration of DMSO was 0.1%.  
4.2.2.1 Cell lines 
Cell line details are given in Chapter 2. Two cell lines SH-SY5Y and C6-STX 
were selected for these studies as examples of high polyST expression, whilst 
C6-WT was used as a low expressing negative control. Unless specified, cells 
were cultured in their specified medium as described in section 2.2.3.1. 
4.2.2.2 MTT assay 
Cell cytotoxicity was assessed in polySia positive cells (IMR-32, SH-SY5Y, C6-
STX) and polySia negative cells (C6-WT) using the MTT assay as described in 
section 2.2.3.3.  
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Cells were treated with the novel compounds at the following concentrations: 1, 
5, 10, 50 and 100 µM, and microplates evaluated spectrophotometrically after 
96 h to determine the long-term effect of the compounds on cells. Since for the 
invasion assay a 24 h time course was used, the MTT assay was also 
performed for 24 h to determine the short term effect of the novel polySTi. After 
24 h media was aspirated and replaced with fresh medium and incubated and 
the plate was read after 96 h. 
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Table 4.2: Compounds evulated in this thesis. 
N-acylmannosamine 
analogues 
Rationally designed 
inhibitors 
Tool compound 
 
ICT3149 
 
 
 
ICT3125 
 
CMP 
 
 
ICT3128 
 
 
ICT3126  
 
ICT3172   
 
ICT3176 
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4.2.3 Determining the specificity of novel inhibitors for α-2,8-polyST  
Compound specificity for α-2,8-polyST was characterised as specified in 
Chapter 2. Effects on other sialic acids were evaluated using Maackia 
amurensis isoforms and Sambucus nigra, which detect α-2,3 and α-2,6 sialic 
acids respectively. Cell cultures were treated with 100 µM of compound for 24 h 
and then administered as stated in section 2.2.6. 
4.2.4 Evaluation of polySTi efficacy and specificity 
4.2.4.1 PolySia knockdown assay  
The effect of the novel compounds on polySia tumour cell surface expression 
was evaluated on polySia expressing cells SH-SY5Y and C6-STX using the 
recovery assay as defined in Chapter 3. 
Briefly, cells were treated with endo-N for 24 h to remove polySia and cultures 
fixed directly to confirm removal of polySia. Cultures were treated with endo-N 
first and then incubated with medium (polySia recovery) or exposed to different 
concentrations of agent (50 µM and 100 µM) following 6 h incubation time. Then 
cultures were processed through the polySia recovery assay using CMP 
(cytidine monophosphate as tool compound) at 5 mM described in section 
3.2.2.  
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4.2.4.2 Analysis of the effects of the novel compounds on polySia 
mediated cell invasion 
The effect of novel agents on polySia mediated invasion was tested using the 
Matrigel invasion assay as described in Chapter 3. In the Matrigel invasion 
assay, Matrigel coated inserts were prepared by adding 0.1 ml of Matrigel 
solution (250 µg/ml) to the transwell and allowing the Matrigel to dry at 37°C in 
a non-humidified oven for 2 h. Cells were starved for 4 h in serum free medium. 
Trypsinized cells were suspended in serum free medium and cells were added 
to the upper chamber of transwells with medium or polySTi (100 µM). Medium 
with 10% FBS was added to the lower chamber. After 24 h, transwell were 
processed as described in section 3.2.3.1. Here, CMP at 5 mM was used as a 
positive control. 
4.2.5 Statistical analysis 
Each experiment was performed in triplicate. Results are presented as mean ± 
SD. Quantifiable data were subjected to the Student's t-test for statistical 
significance. Differences were considered statistically significant (p<0.05) as 
used in literature (Kiss et al, 1994; Joshi et al, 2005). 
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4.3 Results 
4.3.1 Evaluation of cytotoxicity of novel compounds using the MTT assay  
IMR-32, C6-STX, SH-SY5Y and C6-WT cells were exposed to novel 
compounds for 96 h (Figure 4.2). Minimal cytotoxicity was seen with the 
majority of the compounds evaluated as an IC50 was not achieved, even for the 
highest concentration used, 100 µM.  
IC50 values were achieved for two compounds for 96 h exposure; ICT3176 and 
ICT3172 have IC50 less than 100 µM (Table 4.3). ICT3176 IC50 values were 
achieved in IMR-32 (90 µM) and C6-STX (90 µM), whilst for ICT3172 IC50 
values were seen for in IMR-32 (50 µM), SH-SY5Y (30 µM) and C6-STX (40 
µM) (Table 4.3). 
The assays used in this thesis have compound exposure lasting for 24 h. Since 
cytotoxicity was clearly seen for 96 h exposures and this may result in an issue 
with longer exposure time in the assay. Therefore, SH-SY5Y, C6-STX and C6-
WT cells were exposed to compounds for 24 h: no IC50 values were obtained 
from three independent experiments on SH-SY5Y, C6-STX and C6-WT cells, 
giving confidence that any inhibitory effects (i.e. reduction in polySia surface 
expression or cell invasion) of ICT compounds will be as a result of polyST 
inhibition, not compound cytotoxicity (Figure 4.3).  
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Figure 4.2: Evaluation of novel compound cytotoxicity (96 h). 
IMR-32, SH-SY5Y, C6-STX and C6-WT cells were incubated with different 
concentrations of compound and were assessed using the MTT assay as 
described in the Materials and Methods. The results are expressed as 
percentage of cell survival (n=3). 
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Figure 4.3: Evaluation of novel compound cytotoxicity (24 h). 
A graphic presentation of SH-SY5Y, C6-STX and C6-WT cell lines were 
exposed to increasing concentration of six novel compounds. The results are 
expressed as percentage of cell survival. 
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Table 4.3: Cytotoxicity IC50 (IC50 ± SD) values of novel compounds towards tumour cells at 96 h incubation 
period as determined by the MTT assay (n=3).  
Novel compound IMR-32 SH-SY5Y C6-STX C6-WT 
ICT3176 90 µM ± 29.96 >100 µM 90 µM ± 8.35 >100 µM 
ICT3172 50 µM ± 30.24 30 µM ± 5.85 40 µM ± 11.42 >100 µM 
ICT3126 >100 µM >100 µM >100 µM >100 µM 
ICT3128 >100 µM >100 µM >100 µM >100 µM 
ICT3125 >100 µM >100 µM >100 µM >100 µM 
ICT3149 >100 µM >100 µM >100 µM 75 µM ± 26.69 
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4.3.2 Novel compounds demonstrate no effect on α-2,3 and α-2,6 sialic 
acid expression  
SH-SY5Y, C6-STX and C6-WT cells were also subjected to a staining 
procedure based on the sialic acid-specific lectins, SNA and MAL I and MAL II, 
which is specific for α-2,6-linked and the latter α-2,3-linked sialic acids shown in 
Figure 4.4. Six potential polySTi, namely: ICT3172, ICT3176, ICT3126, 
ICT3128, ICT3125 and ICT3149 were screened at a non-toxic concentration, 
100 µM.  
Treatment of potential polySTi had no significant effect on α-2,6-linked and α-
2,3-linked sialic acid expression as judged by lectin staining specific for these 
Sias. This suggested that these inhibitors are specific for α-2,8-polyST as 
confirmed by the quantification of expression shown in Figure 4.4D.  
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Figure 4.4: Effect of potential polySTi on expression of α-2,3 and α-2,6 sialic acids, as determined by lectin staining.  
(A) SH-SY5Y, (B) C6-STX and (C) C6-WT cells were stained with Maackia amurensis agglutinin (MAL) in its two isoforms MAL I and 
MAL II to detect the expression of α-2,3-linked sialic acids and with Sambucus nigra agglutinin (SNA) to detect the expression of α-2,6 
linked sialic acid. (D) Quantitative analysis of cells after 24 h polySTi treatment. There was no significant reduction seen in the 
expression of other sialic acids. Data is represented as mean ± SD of three independent experiments. 
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4.3.3 Evaluation of effects of novel agents on cellular polySia expression    
Using the recovery assay developed in Chapter 3, the effects of novel 
compounds on modulation of polySia cell surface expression were evaluated. 
First, cell surface polySia expression was removed by endo-N and then its re-
expression was explored in the absence or presence of different potential 
polySTi. The non-toxic concentrations 50 and 100 μM (see Figure 4.3) were 
selected for 24 h treatment.  
In untreated SH-SY5Y and C6-STX cells, tumour cell surface polySia 
expression had recovered in 6 h whereas cells treated with potential polySTi 
showed an absence of polySia (Figure 4.5 and Figure 4.6). At the highest 
concentration, ICT3176 (~60%) and ICT3172 (~65%) markedly halted polySia 
re-expression in SH-SY5Y cells. Other novel polySTi were less effective in SH-
SY5Y cells (Figure 4.5) at the concentrations tested. With C6-STX cells, similar 
results were seen. No cytotoxicity was seen confirming that the absence of 
polySia is likely to be to the inhibition of polyST. ICT3128 also affected polySia 
re-expression of C6-STX cells more than SH-SY5Y cells (Figure 4.6, p<0.05). 
ICT3176 was the most potent novel compound evaluated.  
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Figure 4.5: Effect of potential polySTi on polySia re-expression of SH-
SY5Y cells using the polySia recovery assay. 
(A) Cells were treated with endo-N for 24 h, rinsed and allowed to recover with 
medium or compound. Control data was not treated with endo-N. Quantification 
of SH-SY5Y cells represents the sum of polySia expression divided by sum of 
nucleus (DAPI) (B). Data was normalised to the result observed with untreated 
cells (positive control) and represents as mean ± SD. Statistically significant 
results were obtained with CMP (**p<0.05) and all ICT compounds tested at 
100 µM, as compared with untreated cells (positive control) (p<0.05, indicated 
by *). ICT3176, ICT3172 and ICT3128 produced statistically significant 
inhibition at 50 µM (p<0.05, indicated by #). 
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Figure 4.6: Effect of novel compounds on polySia re-expression of C6-
STX cells using the polySia recovery assay. 
C6-STX cells were treated with endo-N for 24 h, rinsed and allowed to recover 
with medium or novel compounds (A). Control data was not treated with endo-
N. Quantification of C6-STX cells represents the sum of polySia expression 
divided by sum of nucleus (DAPI) (B). Data was normalised to the result 
observed with untreated cells (positive control) and represents as mean ± SD. 
Statistically significant results were obtained with ICT3176, ICT3172, ICT3128 
and ICT3126 at 100 µM, as compared with untreated cells (positive control) 
(p<0.05, indicated by *). ICT3176, ICT3126 and ICT3172 produced statistically 
significant inhibition at 50 µM (p<0.05, indicated by #). 
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4.3.4 Novel compounds reduce SH-SY5Y and C6-STX invasion 
Next, the effect of novel polySTi on polySia dependent invasion was examined 
using the Matrigel invasion assay.  
Cells were exposed to non-cytotoxic doses of polySTi, 100 µM (see Figure 4.3) 
for 24 h treatment.  
As shown in Figure 4.7, the number of invading cells observed in seven 
random microscopic fields in the Matrigel invasion assay was also significantly 
reduced (p<0.05 in relation to untreated control) by ICT3176 and ICT3172 in 
SH-SY5Y and C6-STX cells at 100 µM.  
ICT3149 showed a lower inhibitory effect in invasion in C6-STX and SH-SY5Y 
cells at the concentration tested. No effect of novel compounds was seen for 
C6-WT (polySia and polyST negative) cells invasion. 
No cytotoxicity was observed in any of the experiments.  
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SH-SY5Y, C6-STX and C6-WT cells incubated with novel compound (100 µM) for 24 h. Cells invading the lower surface of the Boyden 
chamber were stained with DAPI and images were captured under a microscope (magnification, X20) (A). Invaded cells were counted 
and normalized to the result observed in untreated cells where *p<0.05 is considered significant (B). All the data results are from three 
independent experiments and represented as mean ± SD. Scale bar: 50 µm. 
Figure 4.7: Evaluation of invasion of tumour cells following novel agents treatment. 
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4.4 Discussion 
Many elegant studies have demonstrated the flexibility of the incorporation of 
unnatural Sia in the biosynthetic pathway of Sia (Charter et al., 2002, Liu et al., 
2000, Mahal et al., 2001). More than twenty years ago, (Kayser et al., 1992) 
described the novel tool (synthetic N-acyl mannosamines; ManNProp) to 
characterise the biological functions of Sia.  
Many studies have published data about ManNProp (acts as polySia pathway 
inhibitor) reducing migration in IMR-32 cells (Seifert et al., 2012) and reduction 
in cell surface polysialylation, invasion and migration in neuroblastoma SH-
SY5Y cells (Gnanapragassam et al., 2014). These studies used high 
concentrations of ManNProp (up to 10 mM) in cell-based assays, including cell 
toxicity, proliferation, migration and invasion (Gnanapragassam et al., 2014, 
Seifert et al., 2012). Higher millimolar concentrations were required by these 
studies to inhibit or reduce polysialylation, due to the highly hydrophilic nature of 
molecules (they are sugars). These concentrations of Sia precursors are 
considerably higher than typically required for clinically-used drugs such as 5-
fluorouracil or cisplatin (Gnanapragassam et al., 2014), but nevertheless these 
molecules are useful as molecular tools to study biological effects of 
polysialylation.  
At the ICT, a series of N-acylmannosamine precursors were designed and 
synthesised with design features to aid entry of the compound into cells. These 
molecules were modified precursors (acetylated) of ManNProp, successfully 
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resulting in a reduction in the concentrations required to produce biological 
effects at micromolar levels. This was due to an increase in lipophilicity and thus 
membrane permeability, allowing these compounds to enter into cells more 
easily.  
Preliminary screening of potential polySTi using the MTT assay showed an 
absence of toxicity with short term treatment (24 h) whereas slight toxicity was 
observed with a long term treatment (96 h) of ICT3172 and ICT3176 in IMR-32, 
SH-SY5Y and C6-STX cells. This cytotoxicity was observed previously: for 
example a study by Liu et al (2000) showed that leukaemia (RMA) cells were 
similarly affected by ManNProp. Therefore, the effects seen for the novel 
compound ICT3176 was most likely due to inhibition of polyST (leading to 
reduction of the polySia surface expression and as a consequence invasion) in 
polySia expressing SH-SY5Y and C6-STX cells, instead of due to the 
compound toxicity.  
CMP, previously identified as a competitive polyST inhibitor (Al-Saraireh et al., 
2013), was additionally evaluated. The CMP concentration used in this study 
showed no cytotoxic effect on these same cell lines. Since IMR-32 cells grow in 
clumps and thus do not form monolayers, they were not further utilised in the 
recovery and invasion assays.   
The specificity of potential polySTi for α-2,8-polyST was confirmed, with no 
effect on α-2,3-ST or α-2,6-ST, as determined by absence of effect on the 
expression of α-2,3 (using MAL I, MAL II) or α-2,6 sialic acid (using SNA).  
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Therefore, the effect of novel agents was further investigated using the polySia 
recovery assay. The results indicated the different polySTi had differing effects 
on the recovery of polySia. Significant inhibition of polySia cell surface recovery 
was observed following ICT3176 and ICT3172 treatment in both polySia 
positive cells, whereas no effect was seen in C6-WT cells.  
ICT3149 had the lowest effect on SH-SY5Y and C6-STX polySia cell-surface 
expression at the concentrations tested. This was predicted, since ICT3149 is a 
precursor to the natural substrate (acetylated ManNAc), and so effectively 
increases the concentration of Sia/polySia in cells. The slight inhibitory effects 
seen on invasion may be the result of altered cell-cell or cell-matrix adhesion, 
which result from increased polySia expression. This requires further 
investigation (Liu et al., 2000). ICT3128 is the acetylated version of ManNProp 
and had some reasonable effect on SH-SY5Y and C6-STX cells, at the lower 
(µM) concentrations previously described.  
As shown in Figure 4.5 and Figure 4.6, ICT3176 and ICT3172 produced the 
highest reduction in tumour cell surface polySia expression. These molecules 
are analogues of ICT3128, in which the propyl group has been substituted for 
an alkyl and aromatic substituent respectively. These agents emerged as the 
most promising from a wider panel of ManNProp derivatives. 
In the polySia recovery assay, anti-polySia antibody (mAb 735) was used, 
which is specific to native polySia (Frosch et al., 1985). Using other antibodies, 
such as monoclonal anti-N-propanoyl neuraminic acid antibody (mAb 13D9), 
could be useful to assess the effect of certain polySTi on polySia biosynthesis. 
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MAb 13D9 was generated against meningitis and (details in Table 2.1) 
specifically recognises extended epitopes (e.g. N-propionyl-PolySia, Neu5Prop, 
which could result from ManNprop treatment) (Pon et al., 1997), since mAb 735 
does not recognise polySia exclusively with elongated N-acyl chains (Liu et al., 
2000). Both antibodies have been used together previously to study N-acyl 
sialic acid precursor treatment (Pon et al., 2007). The specificities of these 
antibodies would allow us to investigate the incorporation of unnatural Sia 
precursors into polySia chains and alternation on polySia cell surface to its 
analogue required further investigation. 
Interestingly, acetylated N-acylmannosamine-based polyST inhibitors reduced 
the invasion ability of the SH-SY5Y and C6-STX cells, which express a 
significant amount polySia and STX. Different novel polySTi did show similar 
effects in the recovery assay.  
As shown in Figure 4.7, ICT3149, ICT3125, ICT3128, ICT3126, at 100 µM were 
not as effective in inhibiting SH-SY5Y and C6-STX invasion compared to 
ICT3172 and ICT3176. These effects suggest that these particular acetylated 
molecules possess more desirable characteristics in terms of their N-acyl side-
chains, to achieve polyST inhibition. This was in agreement with effects 
observed previously by the Horstkorte group, where ManNProp was shown to 
be able to interfere with polysialylation, but only in STX expressing cells 
(Horstkorte et al., 2004a).  
Furthermore, this data is consistent with earlier studies which have used 
ManNProp, which demonstrates that the down-regulation of polysialylation is a 
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useful tool to control tumour migration and invasion (Gnanapragassam et al., 
2014, Seifert et al., 2012). Thus, ICT3176 and ICT3172 were the most 
functionally effective inhibitors of polyST, with no cytotoxic effects observed on 
the concentrations used in the cells studies here.     
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4.5 Conclusion  
In this study, six novel potential inhibitors of polyST were screened in the 
polySia recovery and invasion assays. Two compounds ICT3176 and ICT3172, 
demonstrated a significant reduction in tumour cell surface polySia expression 
and invasion of SH-SY5Y and C6-STX cells. Specificity of polySTi for α-2,8-
polyST over other STs was confirmed by lack of effect on α-2,3 and α-2,6 sialic 
acids expression. 
Acetylated N-acylmannosamines are useful tools to study the effects of polyST 
inhibition on cell function. Although these molecules are hydrophilic, they 
possess sufficient lipophilicity to be used at micromolar concentrations. Further 
investigation of these interesting molecules is warranted to determine whether 
they possess the desired characteristics to be evaluated in vivo. 
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5 Discussion and Future perspective 
5.1 General discussion 
In recent decades, there have been significant developments in the 
understanding of the clinical biology of neuroblastoma. This has led to current 
therapeutic approaches used for high-risk patients, which incorporate induction 
chemotherapy (high dose chemotherapy), local treatment with surgical 
resection and radiotherapy, and maintenance therapy 13-cis-RA and 
immunotherapy, as reviewed in Chapter 1. Despite these options, many 
neuroblastoma patients still have a poor prognosis (Brodeur, 2003). 
Furthermore, these drugs have had limited success caused by complications 
including high tone deafness (Pearson et al., 1992), secondary cancer (Kushner 
et al., 1998), infection and acute toxicity (including bone pain and allergic 
reaction) (Modak and Cheung, 2010). Due to these limiting toxicities, the 
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introduction of further cytotoxic chemotherapy is not considered feasible (Ishola 
and Chung, 2007).  
Despite some success with these treatments it is estimated that 50% of high-
risk patients suffer relapse (Maris, 2010) and hence new approaches are being 
explored to treat this ailment. The biggest challenge is to bridge the gap 
between understanding the neuroblastoma biology and developing effective 
therapies. The predominant hallmark of neuroblastoma is metastasis. 
Prevention of tumour progression by targeting dissemination could be a 
powerful approach to treating patients, especially in high-risk neuroblastoma 
patients.  
One option for the timing of therapeutic intervention by an agent lacking 
cytotoxicity to target metastasis in neuroblastoma, would be after initial 
treatment to remove the primary tumour through surgery, when minimal residual 
disease (MRD) is a concern. Such a therapy would provide a good opportunity 
to manage this disease (Weinstein et al., 2003, Matthay et al., 1999). Indeed 
this is the period when other novel agents have been administered. For 
example, anti-GD2 (ganglioside) antibody therapy and 13-cis-RA have been 
shown to be effective in the MRD setting (Reynolds, 2004, Yu et al., 2010). The 
presence of neuroblastoma cells in peripheral blood circulation could be 
monitored to evaluate the effects of therapy (e.g. using STX, polySia or GD2 
mRNA as a surrogate marker) (Reynolds, 2004), with an expectation of 
reduction of circulating cells with efficacy of adjuvant therapies (Cheung et al., 
2003). 
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Despite these new therapies, neuroblastoma recurrence from MRD after 
treatment remains a significant problem. One possibility is that MRD is thought 
to result from tumour-initiating cells which are drug resistant (Hartomo et al., 
2013). Another possibility is the failure of the immune system to recognise 
neuroblastoma cells. This is possibly due to gangliosides and sialic acids 
(important for metastasis) expressed on tumour cells enabling evasion of the 
immune system (Cheung and Dyer, 2013, Potapenko et al., 2007). 
Targeting specific pathways and associated molecules could provide insights 
into developing biologically-based therapies to control MRD in high-risk 
neuroblastoma patients. For example, retinoids are natural and synthetic 
derivatives of vitamin A, known to induce neuroblastoma cell differentiation in 
vitro (Sidell et al., 1983). These include all trans-retinoic acid (ATRA), 13-cis-RA 
and fenretinide (4-HPR) (Reynolds et al., 2003). The first clinical trial carried out 
by Matthay et al (1999) showed 13-cis-RA to induce apoptosis (rather than 
differentiation) and increase survival in high-risk neuroblastoma patients, 
following bone marrow transplantation (Matthay et al., 1999, Weinstein et al., 
2003). Indeed, 13-cis-RA is now part of the standard treatment protocol for 
high-risk neuroblastoma in an effort to reduce MRD (Brodeur and Bagatell, 
2014, Matthay et al., 2009). Fenretinide (a synthetic retinoid) might have activity 
for MRD by inducing apoptosis in neuroblastoma cells and is currently in 
paediatric Phase I studies (Villablanca et al., 2011).  
Other agents including crizotinib, which target cells with changes in anaplastic 
lymphoma kinase (ALK), a mutation found in 15% of neuroblastoma patients 
(Sahu et al., 2013). This may block cancer cell proliferation by inhibiting 
CHAPTER FIVE 
 
 
152 
 
processes associated with tumour growth and dissemination. Crizotinib is 
currently subject of on-going clinical trials (ClinicalTrials.gov, 2015b, Mossé et 
al., 2013, Krytska et al., 2015).  
Other compound with potential to treat disseminated high-risk neuroblastoma 
patients include vorinostat (a histone deacetylase inhibitor), currently 
undergoing Phase II trials (DuBois et al., 2015). Vorinostat is a small molecule 
which inhibits tumour cell growth by repressing expression of genes (such as 
vascular endothelial growth factor receptor) that are required for growth. The 
agent has shown synergy with 13-cis-RA, which is believed to sensitise tumour 
cells to the drug (ClinicalTrials.gov, 2015a, Ramalingam et al., 2007). Patients 
in Phase I studies showed a complete response to therapy when vorinostat was 
administered with 13-cis-RA in MRD (Fouladi et al., 2010). Phase II studies are 
now underway.  
There is strong evidence that neuroblastoma metastatic behaviour is associated 
with components of the tumour glycocalyx (Berois and Osinaga, 2014). 
Investigations are underway to incorporate immunotherapy targeting surface 
molecules in treating high-risk neuroblastoma patients with MRD. The approach 
already being taken using antibodies targeting ganglioside GD2, a sialic acid-
containing glycosphingolipid, which is overexpressed in neuroblastoma and 
other neuroendocrine tumours (Mujoo et al., 1987). Since GD2 has tumour-
selective expression and as its expression is on the cell surface, this makes it 
an attractive anti-cancer immunotherapy, since anti-GD2 antibodies can 
mediate neuroblastoma cell lysis by two mechanisms including complement-
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dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity 
(ADCC) (Mujoo et al., 1987).  
Immunotherapy is now part of mainstream neuroblastoma therapy, with Unituxin 
(the tradename for the GD2-binding monoclonal antibody) having been 
approved this year by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) (FDA, 2015, EMA, 2015). Two types of 
anti-GD2 antibody (chimeric (ch)14.18 and mouse 3F8) were tested in clinical 
trials extensively. The combination of 3F8 with granulocyte-macrophage colony 
stimulating factor (GM-CSF) and 13-cis-RA showed an 80% overall survival rate 
after first remission in high-risk patients (Cheung et al., 2012). Ch14.18 
administered with interleukin-2, GM-CSF and 13-cis-RA was also proven to be 
effective in randomised trails (Yu et al., 2010). These studies suggested a 
significant improvement with combinational therapy in high-risk neuroblastoma 
patients, in the MRD setting. The clinical trials additionally showed the approach 
to be safe in children (Kushner et al., 2001, Ozkaynak et al., 2000). The therapy 
does have issues. However, side effects including severe pain, fever, urticaria 
and allergic reactions (pruritus) are all common (Navid et al., 2010). 
As has been reviewed in this thesis, polySia is a key component of the tumour 
glycocalyx, which may equally be amenable to therapeutic intervention. The 
MRD period of treatment provides an opportunity for novel approaches such as 
a polySTi to prevent further metastatic spread. Given that polySia could also 
protect tumour cells from the immune system (Drake et al., 2008), there is 
potential for long-term use as maintenance therapy for high-risk neuroblastoma 
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patients. This novel approach could result in significantly better outcomes for 
high-risk neuroblastoma patients.  
The expression of polysialylated NCAM correlates with high metastatic potential 
and poor prognosis in numerous malignant tumours, including neuroblastoma 
(as reviewed in Chapter 1). Although the precise roles of polySia in 
neuroblastoma tumorigenesis are still being uncovered, it has been postulated 
to be associated with a highly tumorigenic subpopulation of cancer stem cells or 
tumour-initiating cells in another polySia-expressing tumour, namely glioma, 
where these cells promote tumour angiogenesis and resistance of cells to 
therapy (Amoureux et al., 2010, Bao et al., 2008).  
Another possibility is that NCAM polysialylation promotes tumour cell 
dissemination. This is supported by various in vitro and in vivo studies. In vitro, 
the presence of polySia promotes migration (Eggers et al., 2011, Suzuki et al., 
2005). In vivo xenograft studies in neuroblastoma have demonstrated that 
polySia-expressing tumours (LAN-1, LAN-5) demonstrate evidence of 
disseminated micrometastases, something not observed from polySia-NCAM-
negative cell lines (Kelly, SK-N-SH) (Valentiner et al., 2011). Scheidegger et al 
(1994) established two sublines E2 (no polySia expression) and E3 (with 
polySia expression) from a human SCLC-derived cell line NCI-H69. High 
metastatic potential was seen with the E3 clone compared to the E2 clone. 
Daniel et al (2001) described a model of human rhabdomyosarcoma, cell line 
TE671, which expresses polySia and NCAM. Lung metastases were observed 
following intravenous, intramuscular, and intraperitoneal, but not subcutaneous 
(s.c) injection of TE671 cells into nude mice. Repeated injections of endo-N (an 
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enzyme which cleaves polySia from NCAM) led to decrease in polySia 
expression in primary intraperitoneal nodules and ascites; and diminished 
formation of liver or lung metastases. This, along with similar studies, provides 
strong evidence for the association between polySia NCAM expression with 
tumour invasion and metastasis (Suzuki et al., 2005, Daniel et al., 2001, Daniel 
et al., 2000).  
In a series of published studies, it has been suggested that it is possible to 
manipulate NCAM polysialylation regulated by STX through treating cells with 
unnatural Sia precursors, N-acylmannosamines, including ManNProp, resulting 
in low or abrogated expression of polySia (Mahal et al., 2001, Liu et al., 2000, 
Horstkorte et al., 2004a, Charter et al., 2002). For example, the expression and 
function of the polyST enzymes was studied by Horstkorte et al (2004a), who 
showed that treating human embryonic carcinoma cell line (N-T2) cells with 
ManNProp resulted in loss of polySia.  
Evidence was provided that STX was selectively inhibited by the respective 
unnatural N-acyl sialoside, which is metabolically formed from the respective 
precursor N-acyl mannosamine. These molecules can therefore be considered 
as useful chemical tools, with selectivity for STX over PST. This is significant 
since PST (as opposed to STX) is important for the limited polySia expression 
found in the brain post-embryogenesis, which is required for neuronal plasticity 
(Ong et al., 1998).  
With this increasing evidence of polyST inhibition as a therapeutic strategy, the 
ICT has established a programme to identify small molecule inhibitors of 
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polyST. As part of this programme, this project has set out to establish assays 
to assess novel molecules, with some promising and encouraging findings in 
the polySia recovery and invasion assays.  
The use of ManNProp and similar compounds presents as a significant 
challenge in in vitro and in vivo studies. Since these are polar molecules, they 
are poorly suited to crossing lipid membranes. Therefore high (mM) 
concentrations of ManNprop have been used in earlier studies to maximise the 
amount of compound crossing the cell membrane since no known transport 
mechanisms have been identified (Büttner et al., 2002).  
Novel N-acylmannosamines have been synthesised at the ICT, with features 
which should allow the molecules to better cross biological membranes, 
therefore requiring lower concentrations. For example: 5 to 10 mM 
concentration of ManNprop (ICT3147) is required to be effective in the scratch 
assay (in-house data), whereas analogue ICT3176 is shown to be effective at 
100 µM (Chapter 4). This strategy reduces the concentration by a factor of 50-
100 and has been successfully utilised to modulate polySia expression on 
NCAM.  
Recent studies (Seifert et al., 2012, Gnanapragassam et al., 2014) have 
demonstrated that treatment of neuroblastoma cell lines (IMR-32 and SH-SY5Y) 
with ManNprop reduced polySia surface expression, migration and invasion in 
vitro, suggesting that the concept of polyST inhibition has potential for 
neuroblastoma therapy. Similar results were found here with polySia expressing 
neuroblastoma cells (SH-SY5Y) treated with novel agents at 100 µM.  
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The most effective compounds from the panel were ICT3176 and ICT3172, 
which showed significant reductions in polySia tumour surface expression and 
invasion. These compounds possess lipophilic N-acyl side chains, which 
suggest that the N-acyl position of the respective sialic acid may be important 
for polyST inhibitory activity. Other compounds studied proved less potent: 
ICT3128, and ICT3149 each required higher concentrations for activity (see 
Chapter 4). ICT3125 and ICT3126, potential inhibitors identified from virtual 
screening of drug-like structures also proved less potent. However, these 
compounds serve as interesting starting points for future medicinal chemistry. 
Given these encouraging results, a preclinical strategy is required to evaluate 
novel structural iterations of the promising molecules and to progress molecules 
towards the clinical studies. Figure 5.1 shows a typical example of a „screening 
cascade‟. The biological assays specific to a target of interest, in this case is 
polyST will be utilised here. 
At the ICT, small molecules have been designed and synthesised. Then, a cell 
free assay is employed to quantify the polysialylation using a fluorescent 
acceptor, a 1,2-diamino-4,5-methylenedioxy-benzene (DMB)-labelled trimer of 
α-2,8-linked sialic acid (DMB–DP3), which acts as an NCAM substitute and 
primes polyST. The inhibitory activity of potential compounds against polyST is 
determined by quantification of the main product (in this case DMP-DP4) as 
described by Al-Saraireh (2013).  
Next, cytotoxicity was determined using the MTT assay and compounds 
demonstrating little or no toxicity were progressed further, since it would be 
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expected that polySTi should not be toxic to cells. Selected compounds were 
then evaluated in the polySia recovery assay (Chapter 3 and Chapter 4). With 
this assay, the indirect effect of compounds on polySTi was determined by 
inhibiting the recovery of polySia in the presence of polySTi. Compounds were 
then selected for evaluation in assays assessing facets of the tumour 
dissemination process (i.e. adhesion, migration, and invasion).  
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The first step is to identify potential polySTi using a cell-free assay. Then, the 
MTT assay and the recovery assay confirmed non-toxic reduction/inhibition of 
polySia cell surface expression. Progressing down the screening cascade, 
reduction in polysialylation NCAM analysed using in vitro tumour 
dissemination assay. Compounds with reasonable activity and ADME features 
will process to in vivo assay to determine maximum dose, toxicity, and PD 
profile. (Green: in-house data; red: this thesis data; black: future work). 
 
Keywords: MTD: Maximum tolerance dose; ADME: absorption, distribution, 
metabolism and excretion; CYP: Cytochrome P450; PD: Pharmacodynamics; 
PK: Pharmacokinetics.  
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Figure 5.1: An example of a representative screening cascade could be 
potential used for identify small molecule polySTi. 
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As has been discussed, metastasis is a multi-faceted process, including 
invasion and migration of tumour cells. Inhibiting neuroblastoma cell invasion 
would provide therapeutic benefit for neuroblastoma patients. Tumour cell 
invasion was the focus of this study, primarily using a Matrigel-based transwell 
assay (Chapter 3). Future work for novel compound effects in other facets of the 
metastatic process will also need to be examined. Assays including those 
studying migration and adhesion are described in section 5.2. 
Once a compound has shown activity in the above assays (i.e. reduction of 
polySia-NCAM expression and functional evidence of reduction of the 
metastatic process under evaluation), there is a need to consider the potential 
issues with metabolism before processing to next stage, in vivo screening. 
Various assays would focus on assessing the potential compound liabilities and 
it is important to predict appropriate features of compounds with respect of 
ADME (absorption, distribution, metabolism and excretion). A cytochrome P450 
(CYP) assay could predict toxic and cellular metabolic effects caused by novel 
compounds as CYPs are key enzymes in the liver involved in drug metabolism 
(Hoelder et al., 2012). The stability of the drug could be determined using liver 
microsomes/hepatocytes (containing metabolising enzymes) which would allow 
us to predict compound clearance (Li, 2005) and potential toxicity (Hughes and 
Karlén, 2014). Solubility and permeability are important factors to determine the 
potential of a compound to be drug-like enough to be tested. A stable and 
soluble compound could potentially be administered systemically or orally. 
In the case of this thesis, the novel polySTi ICT3176 is a carbohydrate probe. It 
has some water solubility and has been modified by acetate groups to increase 
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hydrophobicity (thereby enhancing membrane permeability). These changes 
may affect the pharmacokinetics of this compound sufficiently to allow in vivo 
administration (Ernst and Magnani, 2009). This could be the subject of future 
studies. 
ICT3125, identified via virtual screening, is a more drug-like compound (it is not 
a carbohydrate). The molecule does contain carboxyl group, which will limit its 
cell permeability, possibly resulting in a lack of potency (Chapter 4). Therefore, 
the structure of this compound needs further modification to improve its 
lipophilicity and effectiveness.  
Once the desired in vitro parameters are achieved, the compound can then 
progress to in vivo evaluation as suggested in Figure 5.1. For in vivo studies, 
the selection of the dose level and dosing frequency (drug, stability, amount to 
be given and formulation) is based on the drug maximum tolerated dose (MTD) 
and any dose-limiting toxicities (DLT) (Carter, 1987). The bioavailability of the 
compound, as determined in pharmacokinetic studies, is also important.  
With regard to in vivo studies, a few questions would need to be considered in 
future studies. For example, a method to enable measurement of the effect of 
polyST inhibition would be important, since standard effects on primary tumour 
growth inhibition may be limited. Therefore, pharmacodynamics (PD) assays 
using a biomarker would be useful. Previously it has been mentioned that the 
expression of polysialylated NCAM has been measured in serum, and that this 
correlates with tumour expression in neuroblastoma (Gluer et al., 1998d). This 
could thus be a useful PD marker. Another strategy could be to identify and 
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evaluate a downstream signalling pathway with effects known to be due to 
modulation of polySia on NCAM, as discussed in section 1.6.4. 
In the design of any experiments using animals it is important that 3Rs 
(Reduction, Refinement and Replacement) principles are adhered to. This 
principle was first proposed by Russell and Burch (1959), who stated that every 
effort should be made to Replace animal usage with non-sentient alternatives, 
or if animals need to be used in experiments, to Reduce the number of animals 
to a minimum and to Refine experimental procedures so minimum pain and 
distress is caused (Russell and Burch, 1959, Flecknell, 2002). If alternative 
methods could be applied to address the experimental hypothesis e.g. cell 
culture, use of lower organisms human tissue, then these should be considered 
instead of the standard in vivo experiments (Doke and Dhawale, 2015).  
The choice of an appropriate in vivo model is crucial. For evaluation of effects 
on primary tumours then standard s.c transplanted neuroblastoma xenograft 
tumours in immunodeficient mice could be utilised. As an example, evaluation 
of fenretinide in combination with other agents (cisplatin, and vincristine) was 
carried out in SH-SY5Y neuroblastoma xenograft models (in CB17 s.c female 
mice) (Norris et al., 2014).  
In another study, a liver metastases model was developed by injecting tumour 
cells into liver and has also attempted to reconstruct severe combined 
immunodeficiency (SCID) mouse immunity with human killer cells. Using this 
model, anti-GD2 antibody (ch14.18) with interleukin-2 was shown to be more 
effective against neuroblastoma (Sabzevari et al., 1994). 
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Given that the main therapeutic aim with a potential polySTi would be to limit 
tumour dissemination, then a xenograft model may not be ideal, since s.c 
tumours don‟t often metastasize in a manner that reflects the clinical setting 
(Hoffman, 1999). Orthotopic models of neuroblastoma which are metastatic and 
more clinically relevant would thus be a better model, as shown by a study in 
2002 (Khanna et al., 2002). This model is generated by injecting tumour cells 
into the adrenal gland, where 40% of neuroblastoma arises (Maris et al., 2007, 
Teitz et al., 2011). An orthotropic mouse model, using SH-SY5Y neuroblastoma 
cells also implanted in the adrenal gland, was used to examine in vivo 
sensitivity of bortezomib (proteasome inhibitor that blocks cell growth and 
angiogenesis in neuroblastoma) in combination with fenretinide (Pagnan et al., 
2009). The combination of bortezomib and fenretinide acts through activation of 
endoplasmic reticulum (ER) stress genes, resulting in activating apoptosis and 
blocking angiogenesis. This pharmacological combination proved promising as 
a potential neuroblastoma therapy (Pagnan et al., 2009).  
Another study showed the delivery of nanoparticles encapsulating miR-34a 
(pro-apoptotic microRNA) conjugated with a GD2 antibody into a neuroblastoma 
orthotopic xenograft model (NB1691 or SK-N-AS cells implanted behind the left 
adrenal gland), and showed tumour specific delivery resulting in apoptosis and 
reducing tumour growth (Tivnan et al., 2012). Importantly, these studies 
enabled evaluation of both tumour growth and metastasis, in a manner which is 
more clinically relevant to the disease than an s.c xenograft. 
Using these models, the effect of polySTi on metastatic burden could be 
evaluated. Non-invasive imaging methods would be useful for monitoring 
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tumour burden over time, in the same animal following treatment, with clear 
benefits in terms of 3Rs (see above). Examples of non-invasive imaging 
techniques which could be used include magnetic resonance imaging (MRI), 
computed tomography (CT) and bioluminescence. The potential utility of 
bioluminescence in not only to detect neuroblastoma tumours at an early stage, 
but also monitoring disease course, has been demonstrated in a murine model 
of neuroblastoma reported by (Dickson et al., 2007).  
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5.2 Future directions 
Future studies will aim to select and progress polySTi towards clinical 
development, using a screening cascade similar to that described above. The 
experimental models described in this study are simple in vitro and in vivo 
models that allow us to determine the initial effect of potential polySTi on 
polySia tumour expression and facets of the dissemination process. As a result 
of work completed in this thesis, it would be important to perform further studies 
in the short-term to strengthen the promising findings seen. Hence, the 
immediate future of further in vitro evaluation will be focused upon in this 
section, with in vivo models already discussed in previous section. In the 
immediate future, the particular challenges include quantitative analysis of 
polySTi using flow cytometry and effect of potential polySTi on other aspects of 
tumour dissemination (migration and adhesion). PolyST knockdown 
experiments would be useful to confirm the effects observed with inhibitors. 
5.2.1 Confirmation of the effects of potential polySTi using polyST gene 
knock-outs 
Evidence for the effects of potential polySTi have been clearly shown using the 
polySia knockdown assay, in which endo-N removed polySia expression with 
re-expression being monitored in the presence of polySTi. As a further evidence 
of selectivity, small interfering RNA (siRNA) knockdown of the polyST enzymes, 
particularly STX (which is more associated with polySia expression in tumours 
than PST) could be utilised for further validation. This would result in more 
specific direct polyST knock down compared to the indirect polySia knock down 
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with endo-N. This approach has been successfully applied while investigating 
the role of polySia in pancreatic cancer. Results demonstrated that the siRNA 
knock-down of polyST resulted in an absence of polySia expression, and an 
associated reduction in tumour cell migration (Schreiber et al., 2008). Absence 
of any biological effect on such cells following treatment with a polySTi would 
thus confirm selectivity of the compounds.  
5.2.2 Quantitative analysis of polySia expression following polySTi 
treatment 
Two polySia labelling tools have been used, which have different merits. The 
first, mAb 735, is suitable for use in immunofluorescence experiments described 
in this study. The second, endoN-GFP, has been used in flow cytometry 
experiments previously to determine the effect of a known polySTi (CMP) in-
house (Al-Saraireh et al., 2013). The work of this thesis presented semi-
quantitative analysis of detecting polySia expression in a panel of tumour cells 
using the immunofluorescence technique. The main issue with this technique is 
the quality of fluorescent images, in which too much non-specific antibody or a 
higher concentration leads to misjudgement of the locations of molecules (Odell 
and Cook, 2013).  
Alternatively, flow cytometry is a powerful tool, which can give us qualitative and 
quantitative data analysis of other molecules and cytoplasmic components 
(Brown and Wittwer, 2000). For example, the effect of Sia precursors 
(ManNProp, ManNAc and ManNPent) on SH-SY5Y cell surface polySia was 
examined using flow cytometry. The results showed 90% reduction in the 
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amount of polySia following treatment with ManNProp and ManNPent. This 
study shows how the effects of inhibitors on modulating polysialylation can be 
quantified using flow cytometry.  
A previous study has indicated that polySia antibodies have different 
immunospecificity for degree of polymerisation and sialic acid species since the 
minimum chain lengths required for recognition are different (Sato et al., 2000). 
It will be interesting in future work to determine the immunospecificity of other 
anti-polySia antibodies. This is important in determining the effect of polySTi on 
polySia chain length to polySia biological roles using different anti -polySia 
antibodies. Also, the immunostaining of antibodies may be affected by the 
number of polySia chains on NCAM and immunostaining does not give the 
details of polySia structural features (i.e. number of polySia chains per NCAM) 
(Nishimura et al., 2014).  
Therefore, combination analysis of biochemical methods (i.e. Western blotting) 
and chemical methods (i.e. high pressure liquid chromatography) could help us 
to further understanding of the modification or inhibition of polySia chains by 
polySTi. 
5.2.3 Effect of potential polySTi on polySia mediated migration  
In this thesis, tumour cell invasion was the primary focus. Other facets of the 
metastatic process would additionally need to be addressed, including migration 
and adhesion. The scratch assay is a very common method used at the ICT 
and has been utilised to show the inhibitory effect of CMP and other polySTi on 
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polySia-associated tumour cell migration ((Al-Saraireh et al., 2013); in-house 
data). This involves cells being seeded into multi-well plates, allowing cells to 
attach, forming a confluent monolayer. A needle or pipette tip is used to make a 
scratch forming cell-free zone and cells around the edges of the scratch can 
migrate (Yarrow et al., 2004). The scratch assay has also been employed in 
other studies showing that loss of polySia reduced migration and increased 
focal adhesion of tumour cells (Eggers et al., 2011).  
Another commonly used assay in migration is the transwell migration assay, 
which has the similar technical setup mechanism as transwell invasion assay. 
The only difference is that transwell is overlaid by a thin layer of ECM (i.e. 
Matrigel) before seeding the cells in the chamber (Albini et al., 2004, Marshall, 
2011). Both the transwell migration and invasion assay have been successfully 
used to show the effect of 13-cis-RA on migration and invasion of 
neuroblastoma cell lines (IMR-32 and SH-SY5Y) (Joshi et al., 2005). Therefore, 
different in vitro assays can be used to assess the effect of polySTi on polySia 
expressing migration. 
5.2.4 Evaluation of different ECMs as substrate on polySia mediated 
adhesion 
In previous work and also in this thesis, assays have been developed to look at 
two aspects of tumour dissemination. Another aspect, adhesion, has still not 
been fully addressed and is involved in tumour dissemination.  
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Interestingly, Beecken et al (2005) showed that modulating polysialylated 
NCAM resulted in blocking adhesion of several tumour derived cells (i.e. 
neuroblastoma cells UKF-NB-2, UKF-NB-3, and UKF-NB-4) to human umbilical 
vein endothelial cells (HUVEC). Five days administrations of VPA additionally 
delayed growth of neuroblastoma cells (Beecken et al., 2005).   
Another study conducted by Li et al (2011) examined cells expressing polySia in 
terms of migration and invasion on different ECMs (i.e. Matrigel, collagen, and 
heparin). It was demonstrated that polySia activates FGFR and its downstream 
signalling components, PLC-γ, focal adhesion kinase (FAK) and extracellular 
signal-regulated kinase (ERK). The migration of fibroblast (NIH-3T3) cells 
transfected with STX (NIH-3T3-STX) and mock NIH-3T3 cells (NIH-3T3-mock) 
proved similar on different ECMs (fibronectin, VM and heparin). In each case, 
the polySia-expressing cells exhibited higher rates of migration. Effects on cell 
adhesion proved more complex, however.  
Effects of polySia expression on cell adhesion varied according to the ECM 
studied: heparin (high), vibronectin, laminin and collagen IV (moderate) and 
fibronectin (poor). The author concluded that polySia promote cell migration, but 
that this does not strictly depend on its adhesion to different ECM substrates (Li 
et al., 2011). A cell adhesion assay has also been used with fibronectin coating, 
showing that ManNProp treatment affects calcium transport into the ER lumen 
and was thought to interfere with cellular signalling cascades (Horstkorte et al., 
2004b).  
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As described in Chapter 1, polySia inhibits binding of NCAM and modulates 
tumour cell adhesion, migration and invasion. Therefore, polysialylated NCAM 
or downregulation of NCAM facilitates the migration of tumour cells from the 
primary site (Blaheta et al., 2006). Further investigation into the effect of novel 
polyST inhibitors on the ability of tumour cells to adhere to the extracellular 
matrix may provide a greater understanding of the role of polySia in the tumour 
cell dissemination process.  
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5.3 General conclusion 
The inability to control tumour metastasis and subsequent cancer mortality is a 
major challenge. PolyST is a novel and unexplored therapeutic target, which 
plays a key role in neuroblastoma dissemination. The work presented in this 
thesis supports the hypothesis that a polySTi has potential to limit metastatic 
spread. 
Cell-based assays for cell-surface polysialylation and tumour cell invasion have 
been developed and validated, enabling the identification of novel small 
molecule inhibitors of polyST. This study is a first presentation of drug-like 
polySTi having an effect on polySia cell surface expression and invasion. Also, 
this study for the first time demonstrates the selectivity of polySTi for α-2,8-
polyST using a series of three sialic acid binding lectins. ICT3176 was the most 
promising inhibitor identified, with others (e.g. ICT3125) showing potential as 
providing a platform for medicinal chemistry development.  
These results support the targeting of polyST as a therapeutic strategy for 
neuroblastoma and warrant further medicinal chemistry and in vitro and in vivo 
pharmacological investigations to identify a lead polySTi which could ultimately 
progress to the clinic.  
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